



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/743,704	12/22/2003	Tim Keith	2976-4037US1	8966
27123	7590	11/20/2006		
MORGAN & FINNEGAN, L.L.P. 3 WORLD FINANCIAL CENTER NEW YORK, NY 10281-2101				
EXAMINER				
SALMON, KATHERINE D				
ART UNIT		PAPER NUMBER		
1634				

DATE MAILED: 11/20/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>		<b>Applicant(s)</b>	
	10/743,704		KEITH ET AL.	
	<b>Examiner</b>		<b>Art Unit</b>	
	Katherine Salmon		1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 21 September 2006.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1-33 is/are pending in the application.
- 4a) Of the above claim(s) 16-19, 22-26, 28-31 and 33 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-15, 20, 21, 27 and 32 is/are rejected.
- 7) ☒ Claim(s) 13-15, 20 and 21 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 22 December 2003 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)            | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | Paper No(s)/Mail Date. _____                                      |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>12/22/2003</u>  | 6) <input checked="" type="checkbox"/> Other: <u>2 Alignments</u> |

## **DETAILED ACTION**

### ***Election/Restrictions***

1. Applicant's election with traverse of Group I, and SEQ ID No. 4 and the SNP of SEQ ID NO. 49 in the reply filed on 9/21/2006 is acknowledged.

The traversal is on the ground(s) that there is no serious search burden because to search one group the other groups must be considered (p. 3 2<sup>nd</sup> paragraph). The reply asserts the search of DNA and proteins would overlap because the nucleic acids, vectors, and host cells encode and express the product encompassed by the protein claims (p. 3 3<sup>rd</sup> paragraph). The reply asserts the methods of treating Group V use antibodies of Group III having an antigen binding portion to the polypeptides of Group II and nucleic acids of Group I encoded by such polypeptides may be bound (p. 3 last paragraph).

This is not found persuasive because the requirement for restriction mailed on 7/24/2006 details the criteria for separation of the groups based on independent or distinctiveness of the claims and the serious burden of search the groups in combination.

Groups drawn to nucleotides, antibodies, and polypeptides are patentably distinct because they are drawn to different products having different structures and functions. The search for each of the groups presents a serious search burden, as the searches for each are not coextensive in scope. The inventions have different status in the art as shown by their different classifications. The nucleotides and polypeptides are described by sequence information, which must be searched in different databases. There is also

a search burden in the non-patent literature. Prior to the concomitant isolation and expression of the sequence of interest there may be journal articles devoted solely to polypeptides, which would not have described the polynucleotides. Similarly, there may have been "classical" genetics papers with no knowledge of the polypeptide but spoke to the gene. A polypeptide and an antibody that binds to the polypeptide require different searches. An amino acid sequence search of the full-length protein is necessary for a determination of novelty and unobviousness of the protein. However, such a search is not required to identify antibodies. Furthermore, antibodies, which bind to an epitope of a polypeptide of a group, may be known even if the polypeptide is novel. Searching each of these groups is not coextensive and is a serious burden. For example, art relating to the sequence of nucleic acids would not necessarily provide descriptive information for the polypeptide.

Upon further consideration of the elected claims, the examiner decided that a partial rejoinder of the sequences was appropriate. The nucleic acid of SEQ ID No. 1 is the insert from a genomic BAC. The particular nucleic acids of SEQ ID No. 2, 4, 6, 8, and 10 are alternately spliced cDNAs from this sequence. Therefore SEQ IDs No. 1, 2, 4, 6, 8, and 10 will be rejoined. The requirement for a particular SNP, however, is still valid. The sequences of SNPs are each distinct fragments, which must be search individually.

The requirement is still deemed proper and is therefore made FINAL.

Art Unit: 1634

2. Claims 16-19, 22-26, 28-31, and 33 are withdrawn from consideration as being drawn to a nonelected invention.
3. An Action on the merits for Claims 1-15, 20-21, 27, and 32 with the specific SNP of SEQ ID No. 49 is set forth below.

#### ***Claim Interpretation***

4. It is noted that in the parent application, 09/627465 the first action mailed 06/19/2002 rejected SEQ ID No. 1 as being anticipated by BACPAC filters. The rejection was withdrawn in view of applicant's disclosure of an "isolated" nucleic acid in the specification in the following office action mailed 02/10/2003 (see p. 6 of office action and p. 11-12 of reply to office action pointing to definition of "isolated" filed 11/27/2002). Therefore, because of the interpretation of "isolated" already made of record Claim 27 is not being rejected as anticipated by the BACPAC filters.

#### ***Claim Objections***

5. Claims 13-15 are identical to Claims 6-8. Claims 13-15 and Claims 6-8 depend from Claim 5:

Claims 20-21 are objected to because of the following informalities: The claims contain references to sequence and SNP sites described in tables. MPEP 2173(s) states "Where possible, claims are to be complete in themselves. Incorporation by reference to a specific figure or table is permitted only in exceptional circumstances where there is no practical way to define the invention in words and where it is more

Art Unit: 1634

concise to incorporate by reference than duplicating a drawing or table into the claim. Incorporation by reference is a necessity doctrine, not for applicant's convenience." In the instant case it would be possible to refer to the claimed sequences and SNP sites using proper sequence identifiers and phraseology. Appropriate correction is required.

### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claim 21 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 21 is indefinite over the recitation "an isolated variant of SEQ ID No. 4". It is not clear what limits the claim with regard to the polymorphisms. It is not clear what it means for a nucleic acid to "contain" a polymorphism. It would be clearer if applicant required the presence of a polymorphic site as a particular position in a sequence. Clarification is required.

### ***Claim Rejections - 35 USC § 112-Written Description***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 1-15, 20-21, 27, and 32 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claim 1 is drawn to an isolated nucleic acid which may comprise at least 50 nucleotides of SEQ ID No. 2, 4, 6, 8, or 10 or a complementary strand. Claims 2-3 define the nucleic acid. Claims 4-8 identify the vector or host cell. Claim 9 is drawn to at least 50 consecutive nucleotides of SEQ ID No. 2, 4, 6, 8, or 10 or a complementary strand. Claim 10 is drawn to hybridization conditions. Claims 11-15 define vector or host cell. Claims 20-21 are drawn to variants. Claim 27 is drawn to an isolated nucleic acid fragment comprising at least 15 consecutive nucleotide bases of SEQ ID No. 1. Claim 32 is drawn to a kit.

It is noted that nucleic acids consisting of SEQ ID No. 2, 4, 6, 8, or 10 meet the written description requirements. However, none of the instant claims are limited to such a molecule. It is noted that "a complementary nucleic acid sequence" is being broadly interpreted as encompassing any fragment of SEQ ID NO. 2, 4, 6, 8, or 10 and not the full length of the claimed sequences. The claims as written encompass fragments of at least 50 mer of SEQ ID No. 2, 4, 6, 8, or 10; at least 15 mer of SEQ ID No. 1, and any fragment of any length which is a complement of SEQ ID NO. 1, 2, 4, 6, 8, or 10. Therefore the claims as broadly written encompass flanking sequences or unspecified length and identity.

The claims as broadly written encompass isolated nucleic acids comprising fragments of SEQ ID No. 1-2, 4, 6, 8, or 10 without any description of the nucleotides flanking the fragments. The specification does not provide an adequate written description of the claimed genus of nucleic acids as the claims are broadly written.

Additionally, the claims do not set forth the number or identity of nucleotides flanking the recited nucleic acid fragments. Accordingly, the claims encompass nucleic acids which comprise the recited 15 mer fragments of SEQ ID NO: 1 or 50 mer fragments of SEQ ID No. 2, 4,6, 8, 10 but which do not share any overall level of sequence identity with the sequences. The variants may include nucleotide substitutions, additions, deletions, translocations and truncations. The claims thereby encompass naturally and non-naturally occurring allelic, mutant and splice variants of SEQ ID No. 1, 2, 4,6, 8, and 10.

The general knowledge in the art concerning homologues, mutants, allelic and splice variants does not provide any indication of how modification of the sequence of SEQ ID No. 1, 2, 4,6, 8, 10 will affect the functional properties of SEQ ID No. 1, 2, 4,6, 8, 10. The structure and function of one molecule does not provide guidance as to the structure and function of other molecules. Therefore, the description of one molecule (SEQ ID No. 1, 2, 4,6, 8, 10) is not representative of a genus of homologues, splice, mutant and allelic variants of SEQ ID No. 1, 2, 4,6, 8, 10 having unspecified functional activities different from that of SEQ ID No. 1, 2, 4,6, 8, 10. A general statement in the specification of a desire to obtain gene sequences, homologues from other species, mutated species, and polymorphic sequences is not equivalent to providing a clear and



Art Unit: 1634

complete description of specific sequences which fall within the claimed genus of nucleic acids.

In analysis of the claims for compliance with the written description requirement of 35 U.S.C. 112, first paragraph, the written description guidelines note regarding genus/species situations that "Satisfactory disclosure of a ``representative number" depends on whether one of skill in the art would recognize that the applicant was in possession of the necessary common attributes or features of the elements possessed by the members of the genus in view of the species disclosed." (See: Federal Register: December 21, 1999 (Volume 64, Number 244), revised guidelines for written description.) In the instant case, the specification fails to teach the necessary common attributes or features of the genus of encompassed nucleic acids in view of the species disclosed. As such, one of skill in the art would not recognize that applicant was in possession of the detection of ANY fragment of SEQ ID No. 3 or 4.

Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention." (See page 1117). The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See page 1116).

Finally, University of California v. Eli Lilly and Co., 43 USPQ2d 1398, 1404, 1405 held that:

...To fulfill the written description requirement, a patent specification must describe an invention and do so in sufficient detail that one skilled in the art can clearly conclude, "the inventor invented the claimed invention." *Lockwood v. American Airlines, Inc.*, 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (1997); *In re Gosteli*, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989) (" [T]he description must clearly allow

Art Unit: 1634

persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed."). Thus, an applicant complies with the written description requirement "by describing the invention, with all its claimed limitations, not that which makes it obvious," and by using "such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention." *Lockwood*, 107 F.3d at 1572, 41 USPQ2d at 1966.

An adequate written description of a DNA, such as the cDNA of the recombinant plasmids and microorganisms of the '525 patent, "requires a precise definition, such as by structure, formula, chemical name, or physical properties," not a mere wish or plan for obtaining the claimed chemical invention. *Fiers v. Revel*, 984 F.2d 1164, 1171, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993). Accordingly, "an adequate written description of a DNA requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it; what is required is a description of the DNA itself." *Id.* at 1170, 25 USPQ2d at 1606.

The claims do not meet the written description provision of 35 USC 112, first paragraph. Applicant is reminded that Vas-Cath makes clear that the written description provision of 35 USC 112 is severable from its enablement provision. (See page 1115.)

### ***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

8. Claims 1-5, 9-12, 15, 20-21, 27, and 32 are rejected under 35 U.S.C. 102(b) as being anticipated by Shankar et al. (Biochem. J. 1994 Vol 300 p. 295) as evidenced by GenBank Accession Number U14383 (NCBI website December 31, 1994).

Shankar et al. teaches a novel human airway mucin and disclose that this sequence is provided in the GenBank under the accession number U04799 (p. 295). GenBank Accession number U04799 has been replaced by Accession No. U14383 (see Accession No. U14383).

With regard to Claims 1 and 9, GenBank Accession No. U14383 teaches a sequence which is 87.7% similar over the entire length to SEQ ID NO. 4, 82% similar to SEQ ID No. 2, 69.2% similar to SEQ ID Nos 6, 8, and 10. U14383 comprising at least 50 nucleotides which hybridize to SEQ ID No. 4, 2, 6, 8, and 10. U14383 comprising at least 50 nucleotides which hybridize under stringent conditions to SEQ ID No. 2, 4, 6, 8, and 10 (please see attached alignment of GenBank Accession No. U14383 with SEQ ID No. 2, 4, 6, 8, and 10).

With regard to Claim 2, Shanker et al. teaches a nucleic acid sequence which is composed of DNA. With regard to Claim 3, GenBank Accession No. U14383 provides the amino acid sequence; therefore, the isolated nucleic acid which is at least 50 mer could be RNA.

With regard to Claims 4 and 11, Shanker et al. teaches placing the inset into a UniZap vector (expression vector) (p. 296 1<sup>st</sup> column 1st full paragraph). With regard to Claims 5, 8, 12, and 15 Shanker et al. teaches screening the library and selecting positive plaques (host cells) (p. 296 1<sup>st</sup> column 2<sup>nd</sup> full paragraph).

With regard to Claim 10, Shanker et al. teaches a fragment, which has 98% similarity to SEQ ID No. 4, therefore the DNA sequence would hybridize to SEQ ID No. 4 under high stringency conditions. Further note, SEQ ID NO. 2, 6, 8, and 10 are splice

Art Unit: 1634

variants which are 100% identical at nucleotide positions 1-1004 therefore the Shanker et al. fragments would also hybridize to SEQ ID No. 2, 6, 8, and 10.

With regard to Claim 20, GenBank Accession No. U14383 comprises a polynucleotide, which has at least 15 consecutive nucleotide of any of the nucleic acids of Table 5 (SEQ 49) wherein there is a SNP site. The claims do not limit the SNP to a particular type.

U14383	TGTGCACTCTTGG-CATATGCCTAGGAGTGGAAGTCTG	1399
SEQ49	TGTGCACTCTTGGGCATATGCCTAGGAGTGGAAGTCTG	39

As observed above, the nucleotide sequence, U14383, comprises at least 15 nucleotides and there is a SNP (an deletion) at position 1374 of U14383, which is a SNP site for SEQ ID No. 49.

With regard to Claim 21, U14383 comprises a sequence that is 89.5% similar to SEQ ID No. 4; therefore, U14383 is a variant of SEQ ID No. 4. Genbank Accession No. U14383 comprises SEQ ID No. 49 with a SNP variant between the two sequences.

With regard to Claim 27, U14383 comprises at least 15 consecutive nucleotides of SEQ ID No. 1. For example nucleotides 300-419 of U14383 are 100% identical to nucleotides 1780-1899 of SEQ ID No. 1.

With regard to Claim 32, the recitation "for detecting chromosome 12 disorder in a biological sample" has not been given patentable weight because the recitation occurs in the preamble. A preamble is generally not accorded any patentable weight where it merely recites the purpose of a process or the intended use of a structure, and where the body of the claim does not depend on the preamble for completeness but, instead, the process steps or structural limitations are able to stand alone. See *In re Hirao*, 535

Art Unit: 1634

F.2d 67, 190 USPQ 15 (CCPA 1976) and *Kropa v. Robie*, 187 F.2d 150, 152, 88 USPQ 478, 481 (CCPA 1951). Accordingly, the claim language of "detecting chromosome 12 disorder in a biological sample" merely sets forth the intended use or purpose of the claimed kits, but does not limit the scope of the claims. Shanker et al. teaches a RNAagents kit from Promega was used to isolate total RNA (p. 296 1<sup>st</sup> column last full paragraph). Shanker et al. teaches RNA samples isolated were transferred to a nylon membrane and probed with cDNA probes under high-stringency conditions which were labeled with a random primer labeling kit (p. 296 1<sup>st</sup> column last full paragraph). Therefore, Shanker et al. teaches probes and hybridization reagents (random primer labeling kit).

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

9. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation

Art Unit: 1634

under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

10. Claims 6-7 and 13-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shankar et al. (Biochem. J. 1994 Vol 300 p. 295) as evidenced by GenBank Accession Number U14383 (NCBI website December 31, 1994) in view of Lasky et al. (US Patent 5304640 April 19, 1994).

Shankar et al. teaches a novel human airway mucin and disclose that this sequence is provided in the GenBank under the accession number U04799 (p. 295). GenBank Accession number U04799 has been replaced by Accession No. U14383 (see Accession No. U14383).

GenBank Accession No. U14383 teaches a sequence which is 87.7% similar over the entire length to SEQ ID NO. 4, 82% similar to SEQ ID No. 2, 69.2% similar to SEQ ID Nos 6, 8, and 10. U14383 comprising at least 50 nucleotides which hybridize under stringent conditions to SEQ ID No. 4, 2, 6, 8, and 10. U14383 comprising at least 50 nucleotides which hybridize under stringent conditions to SEQ ID No. 2, 4, 6, 8, and 10 (please see attached alignment of GenBank Accession No. U14383 with SEQ ID No. 2, 4, 6, 8, and 10).

Shanker et al. teaches placing the inset into a UniZap vector (expression vector) (p. 296 1<sup>st</sup> column 1st full paragraph). Shanker et al. teaches screening the library and selecting positive plaques (host cells) (p. 296 1<sup>st</sup> column 2<sup>nd</sup> full paragraph).

Shankar et al. does not teach human (eukaryotic) host cells.

However, at the time the invention was made, the transformation of human host cells with vectors comprising nucleic acids encoding human proteins was routine in the art. With regard to Claims 6-7 and 13-14, Lasky et al. teaches, "Typical eukaryotic host cells are mammalian, such as Chinese hamster ovary cells or human embryonic kidney 293 cells (Col. 11, lines 36-38)."

Therefore, It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to have transformed human host cells with vectors comprising the nucleic acid taught by Shankar et al. The ordinary artisan would have been motivated to create such host cells for the benefit of expression the polypeptide encoded by the nucleic acid taught by Shankar et al. in order to characterize and study the polypeptide.

### ***Double Patenting***

11. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140

Art Unit: 1634

F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-15 and 27 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 9, 13-25 of U.S. Patent No. 6737519. Although the conflicting claims are not identical, they are not patentably distinct from each other because the scope of the claimed sequences overlap with each other. Claims 1 and 9 of the instant application are drawn to SEQ ID No. 2, 4, 6, 8, or 10 or a fragment thereof, and stringent conditions. Claim 14 and 22 of the '519 patent are drawn to SEQ ID No. 2 or a fragment of 500 nucleotides or more of SEQ ID No. 2. Since SEQ ID No. 2, 4, 6, 8, and 10 are splice variants of each other and because each sequence share at least 500 bp in common the SEQ ID Nos of the instant application are within the scope of Claim 14 and 22 of the '519 patent. Claims 2-8 and 10-15 of the instant application are drawn to defining the nucleic acid, vector and host cell. These claims are not patentably distinct from Claims 15-21 and 23-25 of the '519 patent. Claim 27 of the instant application is drawn to a fragment of SEQ ID No. 1 of at least 15 consecutive nucleotides. Claims 1, 9, and 13 of the '519 patent are drawn to SEQ ID No. 1 or a fragment of at least 500 nucleotides. The instant Claim 27 would fall into the



Art Unit: 1634

scope of the patented claims because both are drawn to SEQ ID No. 1.

**Conclusion**


12. No Claims are allowed.


13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Katherine Salmon whose telephone number is (571) 272-3316. The examiner can normally be reached on Monday-Friday 8AM-430PM.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on (571) 272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

  
Katherine Salmon  
Examiner  
Art Unit 1634

  
JEANINE A. GOLDBERG  
PRIMARY EXAMINER  
10/30/06

  
RAM R. SHUKLA, PH.D.  
SUPERVISORY PATENT EXAMINER

  
George C. Elliott, Ph.D.  
Director  
Technology Center 1600

OM nucleic - nucleic search, using sw model

Run on: October 24, 2006, 13:12:54 ; Search time 2 Seconds  
 (without alignments)  
 11.718 Million cell updates/sec

Title: U14383  
 Perfect score: 1403  
 Sequence: 1 CCACGAGCTGCCCACGTCCT.....AGGAGTGGAAGTCTGGGTA 1403

Scoring table: IDENTITY\_NUC  
 Gapop 10.0 , Gapext 0.5

Searched: 5 seqs, 8352 residues

Total number of hits satisfying chosen parameters: 10

Minimum DB seq length: 0  
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
 Maximum Match 100%  
 Listing first 5000 summaries

Database : US10743704.seq:\*

Pred. No. is the number of results predicted by chance to have a  
 score greater than or equal to the score of the result being printed,  
 and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	% Query		DB	ID	Description
		Match	Length			
1	1230.4	87.7	1441	1	US-10-743-704-4	Sequence 4, Appli
2	1149.9	82.0	1581	1	US-10-743-704-2	Sequence 2, Appli
3	971.2	69.2	1576	1	US-10-743-704-6	Sequence 6, Appli
4	971.2	69.2	1744	1	US-10-743-704-10	Sequence 10, Appl
5	971.2	69.2	2010	1	US-10-743-704-8	Sequence 8, Appli
c 6	130	9.3	1441	1	US-10-743-704-4	Sequence 4, Appli
c 7	130	9.3	1576	1	US-10-743-704-6	Sequence 6, Appli
c 8	130	9.3	1581	1	US-10-743-704-2	Sequence 2, Appli
c 9	130	9.3	1744	1	US-10-743-704-10	Sequence 10, Appl
c 10	130	9.3	2010	1	US-10-743-704-8	Sequence 8, Appli

#### ALIGNMENTS

RESULT 1  
 US-10-743-704-4

```

; Sequence 4, Application US/10743704
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; APPLICANT: LITTLE, RANDALL D.
; APPLICANT: EERDEWEGH, PAUL VAN
; APPLICANT: DUPUIS, JOSEE
; APPLICANT: DEL MASTRO, RICHARD L.
; APPLICANT: SIMON, JASON
; APPLICANT: ALLEN, KRISTINA
; APPLICANT: PANDIT, SUNIL
; TITLE OF INVENTION: NOVEL HUMAN GENES RELATING TO RESPIRATORY DISEASES AND
OBESITY
; FILE REFERENCE: 2976-4037
; CURRENT APPLICATION NUMBER: US/10/743,704
; CURRENT FILING DATE: 2003-12-22
; PRIOR APPLICATION NUMBER: US/09/627,465
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 60/211,749
; PRIOR FILING DATE: 2000-06-14
; PRIOR APPLICATION NUMBER: 60/146,336
; PRIOR FILING DATE: 1999-07-30
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn Ver 2.1
; SEQ ID NO 4
; LENGTH: 1441
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (3)..(1166)
US-10-743-704-4

```

```

Query Match          87.7%; Score 1230.4; DB 1; Length 1441;
Best Local Similarity 97.2%; Pred. No. 7.2e-07;
Matches 1373; Conservative 0; Mismatches 26; Indels 14; Gaps 12;

```

```

Qy      2 CACGAGCTGCCCACGTCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCCCT 61
        ||||||||||||||||||||||||||||| ||||| ||||||||||||||||||||||| ||
Db      2 CACGAGCTGCCCACGTCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCGT 61

Qy     62 CTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAGGGGACACCGG 121
        ||||||| ||||| ||||| ||||||| ||||||| ||||||| ||||| |||||
Db     62 CTCCAGGAAGGGAC-CCGGGTCCACGAGCTGCCCACGTCTCTCCAGGAAGGGAC-CCGG 119

Qy    122 GTTCATGAGCTGCCCACGCCCTTTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGT 181
        || || ||||| ||||| ||||| ||||| ||||||| ||||||| |||||||
Db    120 GTCCACGAGCTGGCCACGTCTCTGCAGGAAGGGACCCCGGGTCCACGAGCTGCCCACGT 179

Qy    182 CCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCC 241
        ||||||| ||||||| ||||||| ||||||| ||||||| ||||||| |||||||
Db    180 CCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCC 239

Qy    242 CGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCC--GGGTACGAAGTACG 299
        ||||| ||||||| ||||||| ||||||| ||||||| ||||| |||||||
Db    240 CGGGTCCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCCCGGGTCCACGAAGTACG 299

Qy    300 CGTCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAGGGGA 359

```

Db	300	 CGTCCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCACGTCTCTCCAGGAGGGGA	359
Qy	360	CACCGGGTTCACGAGCTGCCACGCCCTCTCCAGGAAGGGACCCCGGGTTCATGAGCTGC	419
Db	360	 CACCGGGTTCACGAGCTGCCACGCCCTCTCCAGGAAGGGACCCCGGGTTCATGAGCTGC	419
Qy	420	CCACGTCTCTCCAGGAAGGGACCCGGGT-CACGAACTGCCACGCCCTCTCCAGGAGGG	478
Db	420	 CCACGTCTCTCCAGGAAGGGACCCGGGTCCACGAACTGCCACGCCCTCTCCAGGAGGG	479
Qy	479	GACCCGGGT-CACGAGCTGCCACGTCTCTCCAGGAAGGGACCCGGGT-CACGAGCTGC	536
Db	480	 GACCCGGGTCCACGAGCTGCCACGTCTCAACGGGAAGGGACCCGGGTCCACGAGCTGC	539
Qy	537	CCACGTCTCTCCAGGAAGGGACCCGGGT-CACGAACTGCCACGCCCTCTCCAGGAGGG	595
Db	540	 CCACGTCTCTCCAGGAAGGGACCCGGGTCCACGAACTGCCACGCCCTCTCCAGGAGGG	599
Qy	596	GACACCGGGTTCACGAGCTGCCACGCCCTCTCCAGGAAGGGACCCCGGGTTCACGAGCT	655
Db	600	 GACACCGGGTTCACGAGCTGCCACGCCCTCTCCAGGAAGGGACCCCGGGTTCACGAGCT	659
Qy	656	GCCACGTCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCACGTCTCTCCAGGA	715
Db	660	 GCCACGTCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCACGTCTCTCCAGGA	719
Qy	716	GGGGACACCGGGTTCACGAGCTGCCACGCCCTCTCCAGGAGGGGACACCGGGTTCACGA	775
Db	720	 GGGGACACCGGGTTCACGAGCTGCCACGCCCTCTCCAGGAGGGGACACCGGGTTCACGA	779
Qy	776	GCTGCCACGTCTCTCCAGGAAGGGACCCGGGT-CACGAGCTGCCACGTCTCTCCAG	834
Db	780	 GCTGCCACGTCTCTCCAGGAAGGGACCCGGGTCCACGAGCTGCCACGTCTCTCCAG	839
Qy	835	GAGGGGACACCGGGTTCACGAGCTGCCACGCACTTTCCAGGAAGGGACCCCGGGTTCAG	894
Db	840	 GAGGGGACACCGGGTTCACGAGCTGCCACGCACTTTCCAGGAAGGGACCCCGGGTTCAG	899
Qy	895	GTCTCTGCCGGCCACATCGTGCCTTTGTGTAAATCAGAAGAAAGATGAGGAACAGGCC	954
Db	900	 GTCTCTGCCGGCCACATCGTGCCTTTGTGTAAATCAGAAGAAAGATGAGGAACAGGCC	959
Qy	955	CTCCTCTCTCTCCAGGCAGGCTTTGGTGGAGGGGCTGGATCTCCTGCCGCACCTTCCCTG	1014
Db	960	 CTCCTCTCTCTCCAGGCAGGCTTTGGTGGAGGGGCTGGATCTCCTGCCGCACCTTCCCTG	1019
Qy	1015	GCA-GGCACCCTGTCGTTGAGCCCCAGAACTGCAGGCGGCCGGCAGAGAAGGGGTCCATG	1073
Db	1020	 GCAGGGCACCTGTCGTTGAGCCCCAGAACTGCAGGCGGCCGGCAGAGAAGGGGTCCATG	1079
Qy	1074	ATGGCGCCTCGGTGCG--GCCTTGACCTGCCCCATGGACCTGGAGACAGGGTTTCTCC	1131
Db	1080	 ATGGCGCCTCGGTGCGCAGCCTTGACCTGCCCCATGGACCTGGAGACAGGGTTTCTCC	1139
Qy	1132	TCATTGGCCAGGCTGGTCTCGAACTCCTGACCTCAGACGATCCACCTGCCTCAGCCTCCC	1191

```

Db      1140 TCATTGGCCAGGCTGGTCTCGAACTCCTGACCTCAGACGATCCACCTGCCTCAGCCTCCC 1199
Qy      1192 GAAGTGTGTTGGGATTACA-GCACGAGCCACTGTGCCCCGGCCATCATTCCCTTTTTACTGCTG 1250
        ||||||||||||||||| |||||||||||||||||||||||||||||||||||||
Db      1200 GAAGTGTGTTGGGATTACAGGCACGAGCCACTGTGCCCCGGCCATCATTCCCTTTTTACTGCTG 1259
Qy      1251 ACTAATAGTCTGCTGTGTGAATCCACCGCTAGAAACCCACTCATCAGTTGATGGTCATGT 1310
        ||||||||||||||||| |||||||||||||||||||||||||||||||||||||
Db      1260 ACTAATAGTCTGCTGTGTGAATCCACCGCTAGAAACCCACTCATCAGTTGATGGTCATGT 1319
Qy      1311 GGGTTGCTTCTCGTATTTCGCTTATTATGAACAGTGCTGGAATAAACGTTTCCTGTGCACTC 1370
        ||||||||| |||||||||||||||||||||||||||||||||||||
Db      1320 GGGTTGCTTCTCGTATTTCGCTTATTATGAACAGTGCTGGAATAAACGTTTCCTGTGCACTC 1379
Qy      1371 TT-GGCATATGCCTAGGAGTGGAAGTCTGGGT 1402
        || ||||||| |||||||||||||||||||||
Db      1380 TTGGGCATACGCCTAGGAGTGGAAGTCTGGGT 1412

```

# RESULT 2

US-10-743-704-2

; Sequence 2, Application US/10743704

; GENERAL INFORMATION:

; APPLICANT: KEITH, TIM

; APPLICANT: LITTLE, RANDALL D.

; APPLICANT: EERDEWEGH, PAUL VAN

; APPLICANT: DUPUIS, JOSEE

; APPLICANT: DEL MASTRO, RICHARD L.

; APPLICANT: SIMON, JASON

; APPLICANT: ALLEN, KRISTINA

; APPLICANT: PANDIT, SUNIL

; TITLE OF INVENTION: NOVEL HUMAN GENES RELATING TO RESPIRATORY DISEASES AND OBESITY

; FILE REFERENCE: 2976-4037

; CURRENT APPLICATION NUMBER: US/10/743,704

; CURRENT FILING DATE: 2003-12-22

; PRIOR APPLICATION NUMBER: US/09/627,465

; PRIOR FILING DATE: 2000-07-28

; PRIOR APPLICATION NUMBER: 60/211,749

; PRIOR FILING DATE: 2000-06-14

; PRIOR APPLICATION NUMBER: 60/146,336

; PRIOR FILING DATE: 1999-07-30

; NUMBER OF SEQ ID NOS: 51

; SOFTWARE: PatentIn Ver 2.1

; SEQ ID NO 2

; LENGTH: 1581

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: CDS

; LOCATION: (3)..(1307)

US-10-743-704-2

Query Match 82.0%; Score 1149.9; DB 1; Length 1581;

Best Local Similarity 88.4%; Pred. No. 2.2e-06;

Matches 1373; Conservative 0; Mismatches 26; Indels 155; Gaps 13;

Qy	2	CACGAGCTGCCCCACGTCTCTCTCCAGGAGGGGACACCGGGTTACAGAGCTGCCCCACGCCCT	61
Db	2	CACGAGCTGCCCCACGTCTCTCTCCAGGAAGGGACCCCGGGTTACAGAGCTGCCCCACGTCTCT	61
Qy	62	CTCCAGGAGGGGACACCGGGTTACAGAGCTGCCCCACGTCTCTCTCCAGGAGGGGACACCGG	121
Db	62	CTCCAGGAAGGGAC - CCGGGTCCACAGAGCTGCCCCACGTCTCTCTCCAGGAAGGGAC - CCGG	119
Qy	122	GTTCATGAGCTGCCCCACGCCCTTTCCAGGAAGGGACCCCGGGTTACAGAGCTGCCCCACGT	181
Db	120	GTCCACGAGCTGGCCACGTCTCTGTCAGGAAGGGACCCCGGGTCCACAGAGCTGCCCCACGT	179
Qy	182	CCTCTCCAGGAAGGGACCCCGGGTTACAGAGCTGCCCCACGTCTCTCTCCAGGAAGGGACCC	241
Db	180	CCTCTCCAGGAAGGGACCCCGGGTTACAGAGCTGCCCCACGTCTCTCTCCAGGAAGGGACCC	239
Qy	242	CGGGTTACAGAGCTGCCCCACGTCTCTCTCCAGGAAGGGACCC - -GGGTCACGAACTGCCCA	299
Db	240	CGGGTCCACGAGCTGCCCCACGTCTCTCTCCAGGAAGGGACCCCGGGTCCACGAACTGCCCA	299
Qy	300	CGTCCTCTCCAGGAAGGGACCCCGGGTTACAGAGCTGCCCCACGTCTCTCTCCAGGAGGGGA	359
Db	300	CGTCCTCTCCAGGAAGGGACCCCGGGTTACAGAGCTGCCCCACGTCTCTCTCCAGGAGGGGA	359
Qy	360	CACCGGGTTACAGAGCTGCCCCACGCCCTCTCTCCAGGAAGGGACCCCGGGTTACATGAGCTGC	419
Db	360	CACCGGGTTACAGAGCTGCCCCACGCCCTCTCTCCAGGAAGGGACCCCGGGTTACATGAGCTGC	419
Qy	420	CCACGTCTCTCTCCAGGAAGGGACCCCGGGT - CACGAACTGCCCACGCCCTCTCTCCAGGAGGG	478
Db	420	CCACGTCTCTCTCCAGGAAGGGACCCCGGGTCCACGAACTGCCCACGCCCTCTCTCCAGGAGGG	479
Qy	479	GACCCGGGT - CACGAGCTGCCCCACGTCTCTCTCCAGGAAGGGACCCCGGGT - CACGAGCTGC	536
Db	480	GACCCGGGTCCACGAGCTGCCCCACGTCTCTCTCAACGGGAAGGGACCCCGGGTCCACGAGCTGC	539
Qy	537	CCACGTCTCTCTCCAGGAAGGGACCCCGGGT - CACGAACTGCCCACGCGCTCTCTCCAGGAGGG	595
Db	540	CCACGTCTCTCTCCAGGAAGGGACCCCGGGTCCACGAACTGCCCACGCGCTCTCTCCAGGAGGG	599
Qy	596	GACACCGGGTTACAGAGCTGCCCCACGCCCTCTCTCCAGGAAGGGACCCCGGGTTACAGAGCT	655
Db	600	GACACCGGGTTACAGAGCTGCCCCACGCCCTCTCTCCAGGAAGGGACCCCGGGTTACAGAGCT	659
Qy	656	GCCCACGTCTCTCTCCAGGAGGGGACACCGGGTTACAGAGCTGCCCCACGTCTCTCTCCAGGA	715
Db	660	GCCCACGTCTCTCTCCAGGAGGGGACACCGGGTTACAGAGCTGCCCCACGTCTCTCTCCAGGA	719
Qy	716	GGGGACACCGGGTTACAGAGCTGCCCCACGCCCTCTCTCCAGGAGGGGACACCGGGTTACGA	775
Db	720	GGGGACACCGGGTTACAGAGCTGCCCCACGCCCTCTCTCCAGGAGGGGACACCGGGTTACGA	779
Qy	776	GCTGCCCACGTCTCTCTCCAGGAAGGGACCCCGGGT - CACGAGCTGCCCCACGTCTCTCTCCAG	834
Db	780	GCTGCCCACGTCTCTCTCCAGGAAGGGACCCCGGGTCCACGAGCTGCCCCACGTCTCTCTCCAG	839
Qy	835	GAGGGGACACCGGGTTACAGAGCTGCCCCACGCACTTTCCAGGAAGGGACCCCGGGTTACG	894

Db	840		GAGGGGACACCGGGTTCACGAGCTGCCACGCACTTTCAGGAAGGGACCCCGGGTTCAG	899
Qy	895		GTCTCCTGCCGGCCACATCGTGCCTTTGTGTAAATCAGAAGAAAGATGAGGAACAGGCC	954
Db	900		GTCTCCTGCCGGCCACATCGTGCCTTTGTGTAAATCAGAAGAAAGATGAGGAACAGGCC	959
Qy	955		CTCCTCTCTCTCCAGGCAGGCTTTGGTGGAGGGGCTGGATCTCCTGCCGCACCTTCCCTG	1014
Db	960		CTCCTCTCTCTCCAGGCAGGCTTTGGTGGAGGGGCTGGATCTCCTGCCGCACCTTCCCTG	1019
Qy	1015		GCA-GGCACCCTGTCGTTGAGCCCCAGAACTGCAGGCGGCCGGCAGAGAAGGGGTCCATG	1073
Db	1020		GCAGGGCACCTGTGCTTGAGCCCCAGAACTGCAGGCGGCCGGCAGAGAAGGGGTCCATG	1079
Qy	1074		ATGGCGCCTCGGTGCG--GCCTTGACCTGCCCCCATGGACCTGG-----	1116
Db	1080		ATGGCGCCTCGGTGCGCAGCCTTGACCTGCCCCCATGGACCTGGGAACCTCCCGGCTCT	1139
Qy	1117		-----	1116
Db	1140		TCCCACTCGGGAAAGGAAGGCTCTGGGCATGGAGGTCGGCCAGGCCCCATCCCCGTACCC	1199
Qy	1117		-----	1116
Db	1200		TGGCCCTTCTTCCTGCTTCTGTGTTGTCAGTCCCCGGGGCCTTTGCACCTGCATTCCCT	1259
Qy	1117		-----AGACAGGGTTTCTCCTCATTGGCCAGGCTGGTCTCGAACTCCTGACCTCAGACG	1170
Db	1260		CTCTCTAGACAGGGTTTCTCCTCATTGGCCAGGCTGGTCTCGAACTCCTGACCTCAGACG	1319
Qy	1171		ATCCACCTGCCTCAGCCTCCCGAAGTGTTGGGATTACA-GCACGAGCCACTGTGCCCGGC	1229
Db	1320		ATCCACCTGCCTCAGCCTCCCGAAGTGTTGGGATTACAGGCACGAGCCACTGTGCCCGGC	1379
Qy	1230		CATCATTCCTTTTTACTGCTGACTAATAGTCTGCTGTGTGAATCCACCGCTAGAAACCCA	1289
Db	1380		CATCATTCCTTTTTACTGCTGACTAATAGTCTGCTGTGTGAATCCACCGCTAGAAACCCA	1439
Qy	1290		CTCATCAGTTGATGGTCATGTGGGTTGCTTCTCGTATTCGCTTATTATGAACAGTGCTGG	1349
Db	1440		CTCATCAGTTGATGGTCATGTGGGTTGCTTCTGCTATTTCGCTTATTATGAACAGTGCTGG	1499
Qy	1350		AATAAACGTTCTGTGCACTCTT-GGCATATGCCTAGGAGTGGAAGTCTGGGT	1402
Db	1500		AATAAACGTTCTGTGCACTCTTGGGCATACGCCTAGGAGTGGAAGTCTGGGT	1553

RESULT 3

US-10-743-704-6

; Sequence 6, Application US/10743704

; GENERAL INFORMATION:

; APPLICANT: KEITH, TIM

; APPLICANT: LITTLE, RANDALL D.

; APPLICANT: EERDEWEGH, PAUL VAN

; APPLICANT: DUPUIS, JOSEE

; APPLICANT: DEL MASTRO, RICHARD L.

```

; APPLICANT: SIMON, JASON
; APPLICANT: ALLEN, KRISTINA
; APPLICANT: PANDIT, SUNIL
; TITLE OF INVENTION: NOVEL HUMAN GENES RELATING TO RESPIRATORY DISEASES AND
OBESITY
; FILE REFERENCE: 2976-4037
; CURRENT APPLICATION NUMBER: US/10/743,704
; CURRENT FILING DATE: 2003-12-22
; PRIOR APPLICATION NUMBER: US/09/627,465
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 60/211,749
; PRIOR FILING DATE: 2000-06-14
; PRIOR APPLICATION NUMBER: 60/146,336
; PRIOR FILING DATE: 1999-07-30
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn Ver 2.1
; SEQ ID NO 6
; LENGTH: 1576
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (3)..(1190)
US-10-743-704-6

```

```

Query Match          69.2%; Score 971.2; DB 1; Length 1576;
Best Local Similarity 96.1%; Pred. No. 3.3e-05;
Matches 1097; Conservative 0; Mismatches 33; Indels 12; Gaps 10;

```

```

Qy      2 CACGAGCTGCCCACGTCCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCCCT 61
        |||||||
Db      2 CACGAGCTGCCCACGTCCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCGT 61

Qy     62 CTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGTCCTCTCCAGGAGGGGACACCGG 121
        |||||||
Db     62 CTCCAGGAAGGGAC-CCGGGTCCACGAGCTGCCCACGTCCTCTCCAGGAAAGGAC-CCGG 119

Qy    122 GTTCATGAGCTGCCCACGCCCTTTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGT 181
        || || |||||
Db    120 GTCCACGAGCTGGCCACGTCTCTGCAGGAAGGGACCCCGGGTCCACGAGCTGCCCACGT 179

Qy    182 CCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCCTCTCCAGGAAGGGACCC 241
        |||||||
Db    180 CCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCCTCTCCAGGAAGGGACCC 239

Qy    242 CGGGTTCACGAGCTGCCCACGTCCTCTCCAGGAAGGGACCC--GGGTACGAAGTACG 299
        |||||
Db    240 CGGGTCCACGAGCTGCCCACGTCCTCTCCAGGAAGGGACCCCGGGTCCACGAAGTACG 299

Qy    300 CGTCCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCCTCTCCAGGAGGGGA 359
        |||||||
Db    300 CGTCCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCCTCTCCAGGAGGGGA 359

Qy    360 CACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCCGGGTTCATGAGCTGC 419
        |||||||
Db    360 CACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCCGGGTTCATGAGCTGC 419

```



Qy	420	CCACGTCTCTCCAGGAAGGGACCCGGGT-CACGAACTGCCCACGCCCTCTCCAGGAGGG	478
Db	420	CCACGTCTCTCCAGGAAGGGACCCGGGTCCACGAACTGCCCACGCCCTCTCCAGGAGGG	479
Qy	479	GACCCGGGT-CACGAGCTGCCCACGTCGTCTCCAGGAAGGGACCCGGGT-CACGAGCTGC	536
Db	480	GACCCGGGTCCACGAGCTGCCCACGTCGTCAACGGGAAGGGACCCGGGTCCACGAGCTGC	539
Qy	537	CCACGTCTCTCCAGGAAGGGACCCGGGT-CACGAACTGCCCACGCGCTCTCCAGGAGGG	595
Db	540	CCACGTCTCTCCAGGAAGGGACCCGGGTCCACGAACTGCCCACGCGCTCTCCAGGAGGG	599
Qy	596	GACACCGGGTTACGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCGGGTTCACGAGCT	655
Db	600	GACACCGGGTTACGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCGGGTTCACGAGCT	659
Qy	656	GCCCACGTCTCTCCAGGAGGGGACACCGGGTTACGAGCTGCCCACGTCTCTCCAGGA	715
Db	660	GCCCACGTCTCTCCAGGAGGGGACACCGGGTTACGAGCTGCCCACGTCTCTCCAGGA	719
Qy	716	GGGGACACCGGGTTACGAGCTGCCCACGCCCTCTCCAGGAGGGGACACCGGGTTACGA	775
Db	720	GGGGACACCGGGTTACGAGCTGCCCACGCCCTCTCCAGGAGGGGACACCGGGTTACGA	779
Qy	776	GCTGCCCACGTCTCTCCAGGAAGGGACCCGGGT-CACGAGCTGCCCACGTCTCTCCAG	834
Db	780	GCTGCCCACGTCTCTCCAGGAAGGGACCCGGGTCCACGAGCTGCCCACGTCTCTCCAG	839
Qy	835	GAGGGGACACCGGGTTACGAGCTGCCCACGCACTTTCCAGGAAGGGACCCCGGGTTACG	894
Db	840	GAGGGGACACCGGGTTACGAGCTGCCCACGCACTTTCCAGGAAGGGACCCCGGGTTACG	899
Qy	895	GTCTCTGCGGCCCCACATCGTGCCTTTGTGTAAATCAGAAGAAAGATGAGGAACAGGCC	954
Db	900	GTCTCTGCGGCCCCACATCGTGCCTTTGTGTAAATCAGAAGAAAGATGAGGAACAGGCC	959
Qy	955	CTCCTCTCTCTCCAGGCAGGCTTTGGTGGAGGGGCTGGATCTCCTGCCGCACCTTCCCTG	1014
Db	960	CTCCTCTCTCTCCAGGCAGGCTTTGGTGGAGGGGCTGGATCTCCTGCCGCACCTTCCCTG	1019
Qy	1015	GCA-GGCACCCTGTCGTTGAGCCCCAGAACTGCAGGCGGCCGGCAGAGAAGGGGTCCATG	1073
Db	1020	GCAGGGCACCCTGTGCTTGAGCCCCAGAACTGCAGGCGGCCGGCAGAGAAGGGGTCCATG	1079
Qy	1074	ATGGCGCCTCGGTGCG--GCCTTGGACCTGCCCCCATGGACCTGGAGACAGGGTTTCTCC	1131
Db	1080	ATGGCGCCTCGGTGCGCAGCCTTGGACCTGCCCCCATGGACCTGGGAACCTCCCGGCTCT	1139
Qy	1132	TC	1133
Db	1140	TC	1141

RESULT 4

US-10-743-704-10

; Sequence 10, Application US/10743704

; GENERAL INFORMATION:

```

; APPLICANT: KEITH, TIM
; APPLICANT: LITTLE, RANDALL D.
; APPLICANT: EERDEWEGH, PAUL VAN
; APPLICANT: DUPUIS, JOSEE
; APPLICANT: DEL MASTRO, RICHARD L.
; APPLICANT: SIMON, JASON
; APPLICANT: ALLEN, KRISTINA
; APPLICANT: PANDIT, SUNIL
; TITLE OF INVENTION: NOVEL HUMAN GENES RELATING TO RESPIRATORY DISEASES AND
OBESITY
; FILE REFERENCE: 2976-4037
; CURRENT APPLICATION NUMBER: US/10/743,704
; CURRENT FILING DATE: 2003-12-22
; PRIOR APPLICATION NUMBER: US/09/627,465
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 60/211,749
; PRIOR FILING DATE: 2000-06-14
; PRIOR APPLICATION NUMBER: 60/146,336
; PRIOR FILING DATE: 1999-07-30
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn Ver 2.1
; SEQ ID NO 10
; LENGTH: 1744
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (3)..(1349)
US-10-743-704-10

```

```

Query Match          69.2%; Score 971.2; DB 1; Length 1744;
Best Local Similarity 96.1%; Pred. No. 3e-05;
Matches 1097; Conservative 0; Mismatches 33; Indels 12; Gaps 10;

```

```

Qy      2 CACGAGCTGCCCACGTCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCCCT 61
        ||||||||||||||||||||||||||||| ||||| ||||||||||||||||||||||| ||
Db      2 CACGAGCTGCCCACGTCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCGT 61

Qy     62 CTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAGGGGACACCGG 121
        ||||||| ||||| ||||| ||||||||||||||||||||||| ||||| ||||
Db     62 CTCCAGGAAGGGAC-CCGGGTCCACGAGCTGCCCACGTCTCTCCAGGAAAGGAC-CCGG 119

Qy    122 GTTCATGAGCTGCCCACGCCCTTTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGT 181
        || || ||||| ||||| ||| || ||||||||||||||||||| |||||||||
Db    120 GTCCACGAGCTGGCCACGTCTCTGCAGGAAGGGACCCCGGGTCCACGAGCTGCCCACGT 179

Qy    182 CCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCC 241
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    180 CCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCC 239

Qy    242 CGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCC--GGGTCACGAAGTCCCCA 299
        ||||| ||||||||||||||||||||||||||||||||||| || |||||||||
Db    240 CGGGTCCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCCCGGGTCCACGAAGTCCCCA 299

Qy    300 CGTCCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAGGGGA 359
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    300 CGTCCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAGGGGA 359

```

Qy	360	CACCGGGTTACAGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCCGGGTTCATGAGCTGC	419
Db	360	CACCGGGTTACAGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCCGGGTTCATGAGCTGC	419
Qy	420	CCACGTCTCTCCAGGAAGGGACCCGGGT-CACGAACTGCCCACGCCCTCTCCAGGAGGG	478
Db	420	CCACGTCTCTCTCCAGGAAGGGACCCGGGTCCACGAACTGCCCACGCCCTCTCCAGGAGGG	479
Qy	479	GACCCGGGT-CACGAGCTGCCCACGTCGTCTCCAGGAAGGGACCCGGGT-CACGAGCTGC	536
Db	480	GACCCGGGTCCACGAGCTGCCCACGTCGTCAACGGGAAGGGACCCGGGTCCACGAGCTGC	539
Qy	537	CCACGTCTCTCTCCAGGAAGGGACCCGGGT-CACGAACTGCCCACGCGCTCTCCAGGAGGG	595
Db	540	CCACGTCTCTCTCCAGGAAGGGACCCGGGTCCACGAACTGCCCACGCGCTCTCCAGGAGGG	599
Qy	596	GACACCGGGTTACAGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCCGGGTTCACGAGCT	655
Db	600	GACACCGGGTTACAGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCCGGGTTCACGAGCT	659
Qy	656	GCCCACGTCTCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGTCTCTCCAGGA	715
Db	660	GCCCACGTCTCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGTCTCTCCAGGA	719
Qy	716	GGGGACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAGGGGACACCGGGTTCACGA	775
Db	720	GGGGACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAGGGGACACCGGGTTCACGA	779
Qy	776	GCTGCCCACGTCTCTCTCCAGGAAGGGACCCGGGT-CACGAGCTGCCCACGTCTCTCCAG	834
Db	780	GCTGCCCACGTCTCTCTCCAGGAAGGGACCCGGGTCCACGAGCTGCCCACGTCTCTCCAG	839
Qy	835	GAGGGGACACCGGGTTCACGAGCTGCCCACGCACTTTCCAGGAAGGGACCCCGGGTTCAG	894
Db	840	GAGGGGACACCGGGTTCACGAGCTGCCCACGCACTTTCCAGGAAGGGACCCCGGGTTCAG	899
Qy	895	GTCTCTGCGGCCCCACATCGTGCCTTTGTGTAAATCAGAAGAAAGATGAGGAACAGGCC	954
Db	900	GTCTCTGCGGCCCCACATCGTGCCTTTGTGTAAATCAGAAGAAAGATGAGGAACAGGCC	959
Qy	955	CTCCTCTCTCTCCAGGCAGGCTTTGGTGGAGGGGCTGGATCTCCTGCCGCACCTTCCCTG	1014
Db	960	CTCCTCTCTCTCCAGGCAGGCTTTGGTGGAGGGGCTGGATCTCCTGCCGCACCTTCCCTG	1019
Qy	1015	GCA-GGCACCCTGTGCTTGAGCCCCAGAAGTGCAGGCGGCCGGCAGAGAAGGGGTCCATG	1073
Db	1020	GCAGGGCACCTGTGCTTGAGCCCCAGAAGTGCAGGCGGCCGGCAGAGAAGGGGTCCATG	1079
Qy	1074	ATGGCGCCTCGGTGCG--GCCTTGACCTGCCCCATGGACCTGGAGACAGGGTTTCTCC	1131
Db	1080	ATGGCGCCTCGGTGCGCAGCCTTGACCTGCCCCATGGACCTGGGAACCTCCCGGCTCT	1139
Qy	1132	TC	1133
Db	1140	TC	1141

RESULT 5

US-10-743-704-8

; Sequence 8, Application US/10743704

; GENERAL INFORMATION:

; APPLICANT: KEITH, TIM

; APPLICANT: LITTLE, RANDALL D.

; APPLICANT: EERDEWEGH, PAUL VAN

; APPLICANT: DUPUIS, JOSEE

; APPLICANT: DEL MASTRO, RICHARD L.

; APPLICANT: SIMON, JASON

; APPLICANT: ALLEN, KRISTINA

; APPLICANT: PANDIT, SUNIL

; TITLE OF INVENTION: NOVEL HUMAN GENES RELATING TO RESPIRATORY DISEASES AND OBESITY

; FILE REFERENCE: 2976-4037

; CURRENT APPLICATION NUMBER: US/10/743,704

; CURRENT FILING DATE: 2003-12-22

; PRIOR APPLICATION NUMBER: US/09/627,465

; PRIOR FILING DATE: 2000-07-28

; PRIOR APPLICATION NUMBER: 60/211,749

; PRIOR FILING DATE: 2000-06-14

; PRIOR APPLICATION NUMBER: 60/146,336

; PRIOR FILING DATE: 1999-07-30

; NUMBER OF SEQ ID NOS: 51

; SOFTWARE: PatentIn Ver 2.1

; SEQ ID NO 8

; LENGTH: 2010

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: CDS

; LOCATION: (3)..(1244)

US-10-743-704-8

Query Match 69.2%; Score 971.2; DB 1; Length 2010;

Best Local Similarity 96.9%; Pred. No. 2.6e-05;

Matches 1091; Conservative 0; Mismatches 23; Indels 12; Gaps 10;

```

Qy      2 CACGAGCTGCCCACGTCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCCCT 61
          |||
Db      2 CACGAGCTGCCCACGTCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCGT 61

Qy     62 CTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAGGGGACACCGG 121
          |||
Db     62 CTCCAGGAAGGGAC-CCGGGTCCACGAGCTGCCCACGTCTCTCCAGGAAAGGAC-CCGG 119

Qy    122 GTTCATGAGCTGCCCACGCCCTTTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGT 181
          |||
Db    120 GTCCACGAGCTGGCCACGTCTCTGCAGGAAGGGACCCCGGGTCCACGAGCTGCCCACGT 179

Qy    182 CCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCC 241
          |||
Db    180 CCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCC 239

Qy    242 CGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCC--GGGTACGAAGTACCA 299
          |||

```

Db 240 CGGGTCCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCCCGGGTCCACGAACTGCCCA 299  
 Qy 300 CGTCCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAGGGGA 359  
 |||||  
 Db 300 CGTCCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAGGGGA 359  
 Qy 360 CACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCCGGGTTCATGAGCTGC 419  
 |||||  
 Db 360 CACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCCGGGTTCATGAGCTGC 419  
 Qy 420 CCACGTCTCTCCAGGAAGGGACCCGGGT-CACGAACTGCCCACGCCCTCTCCAGGAGGG 478  
 |||||  
 Db 420 CCACGTCTCTCCAGGAAGGGACCCGGGTCCACGAACTGCCCACGCCCTCTCCAGGAGGG 479  
 Qy 479 GACCCGGGT-CACGAGCTGCCCACGTCTCTCCAGGAAGGGACCCGGGT-CACGAGCTGC 536  
 |||||  
 Db 480 GACCCGGGTCCACGAGCTGCCCACGTCTCAACGGGAAGGGACCCGGGTCCACGAGCTGC 539  
 Qy 537 CCACGTCTCTCCAGGAAGGGACCCGGGT-CACGAACTGCCCACGCGCTCTCCAGGAGGG 595  
 |||||  
 Db 540 CCACGTCTCTCCAGGAAGGGACCCGGGTCCACGAACTGCCCACGCGCTCTCCAGGAGGG 599  
 Qy 596 GACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCCGGGTTCACGAGCT 655  
 |||||  
 Db 600 GACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCCGGGTTCACGAGCT 659  
 Qy 656 GCCCACGTCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGTCTCTCCAGGA 715  
 |||||  
 Db 660 GCCCACGTCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGTCTCTCCAGGA 719  
 Qy 716 GGGGACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAGGGGACACCGGGTTCACGA 775  
 |||||  
 Db 720 GGGGACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAGGGGACACCGGGTTCACGA 779  
 Qy 776 GCTGCCCACGTCTCTCCAGGAAGGGACCCGGGT-CACGAGCTGCCCACGTCTCTCCAG 834  
 |||||  
 Db 780 GCTGCCCACGTCTCTCCAGGAAGGGACCCGGGTCCACGAGCTGCCCACGTCTCTCCAG 839  
 Qy 835 GAGGGGACACCGGGTTCACGAGCTGCCCACGCACTTTCCAGGAAGGGACCCCGGGTTCAG 894  
 |||||  
 Db 840 GAGGGGACACCGGGTTCACGAGCTGCCCACGCACTTTCCAGGAAGGGACCCCGGGTTCAG 899  
 Qy 895 GTCTCCTGCCGGCCACATCGTGCCTTTGTGTAAATCAGAAGAAAGATGAGGAACAGGCC 954  
 |||||  
 Db 900 GTCTCCTGCCGGCCACATCGTGCCTTTGTGTAAATCAGAAGAAAGATGAGGAACAGGCC 959  
 Qy 955 CTCCTCTCTCTCCAGGCAGGCTTTGGTGGAGGGGCTGGATCTCCTGCCGCACCTTCCCTG 1014  
 |||||  
 Db 960 CTCCTCTCTCTCCAGGCAGGCTTTGGTGGAGGGGCTGGATCTCCTGCCGCACCTTCCCTG 1019  
 Qy 1015 GCA-GGCACCCTGTGCTTGAGCCCCAGAACTGCAGGCGGCCGGCAGAGAAGGGGTCCATG 1073  
 |||||  
 Db 1020 GCAGGGCACCTGTGCTTGAGCCCCAGAACTGCAGGCGGCCGGCAGAGAAGGGGTCCATG 1079  
 Qy 1074 ATGGCGCCTCGGTGCG--GCCTTGGACCTGCCCCATGGACCTGGA 1117  
 |||||  
 Db 1080 ATGGCGCCTCGGTGCGCAGCCTTGGACCTGCCCCATGGACCTGGA 1125

RESULT 6

US-10-743-704-4/c

; Sequence 4, Application US/10743704

; GENERAL INFORMATION:

; APPLICANT: KEITH, TIM

; APPLICANT: LITTLE, RANDALL D.

; APPLICANT: EERDEWEGH, PAUL VAN

; APPLICANT: DUPUIS, JOSEE

; APPLICANT: DEL MASTRO, RICHARD L.

; APPLICANT: SIMON, JASON

; APPLICANT: ALLEN, KRISTINA

; APPLICANT: PANDIT, SUNIL

; TITLE OF INVENTION: NOVEL HUMAN GENES RELATING TO RESPIRATORY DISEASES AND OBESITY

; FILE REFERENCE: 2976-4037

; CURRENT APPLICATION NUMBER: US/10/743,704

; CURRENT FILING DATE: 2003-12-22

; PRIOR APPLICATION NUMBER: US/09/627,465

; PRIOR FILING DATE: 2000-07-28

; PRIOR APPLICATION NUMBER: 60/211,749

; PRIOR FILING DATE: 2000-06-14

; PRIOR APPLICATION NUMBER: 60/146,336

; PRIOR FILING DATE: 1999-07-30

; NUMBER OF SEQ ID NOS: 51

; SOFTWARE: PatentIn Ver 2.1

; SEQ ID NO 4

; LENGTH: 1441

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: CDS

; LOCATION: (3)..(1166)

US-10-743-704-4

Query Match 9.3%; Score 130; DB 1; Length 1441;

Best Local Similarity 51.7%; Pred. No. 5;

Matches 429; Conservative 0; Mismatches 390; Indels 10; Gaps 6;

```

Qy      52 CCCACGCCCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAG 111
      ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||
Db      893 CCGGGGTCCCTTCCTGGAAAGTGCGTGCGGTCAGCTCGTGAACCCGGTGTCCCCTCCTGGAG 834

Qy      112 GGGACACCGGGTTCATGAGCTGCCCCACGCCCTTCCAGGAAGGGACCCCGGGTTCACGAG 171
      ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||
Db      833 AGGACGTGGGCAGCTCGTG-GACCCGGGTCCCTTCCTGGAGAGGACGTGGGCAGCTCGTG 775

Qy      172 CTGCCCACGTCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAG 231
      ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||
Db      774 AACCCGGTGTCCCCTCCTGGAGAGGGCGTGCGGTCAGCTCGTGAACCCGGTGTCCCCTCCTG 715

Qy      232 GAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCCGGG--TCAC 289
      ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||
Db      714 GAGAGGACGTGGGCAGCTCGTGAACCCGGTGTCCCCTCCTGGAGAGGACGTGGGCAGCTC 655

Qy      290 GAACTGCCACGTCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTC 349

```

Db	654	GTGAACCCGGGGTCCCTTCCTGGAGAGGGCGTGGGCAGCTCGTGAACCCGGGTGTCCCCTC	595
Qy	350	CAGGAGGGGACACCGGGTTCACGAGCTGCCCCAGCCCTCTCCAGGAAGGGACCCGGGT	409
Db	594	CTGGAGAGCGCGTGGGCAGTTCGTG-GACCCGGGTCCCTTCCTGGAGAGGACGTGGGCAG	536
Qy	410	CATGAGCTGCCCCACGTCTCTCCAGGAAGGGACCCGGGTACGAACTGCCCCAGCCCTCT	469
Db	535	CTCGTGGACCCGGGTCCCTTCCCGTTGACGACGTGGGCAGCTCGTGGACCCGGGTCCCCT	476
Qy	470	CCAGGAGGGGACCCGGGTACGAGCTGCCCCAGTCGTCTCCAGGAAGGGACCCGGGTCA-	528
Db	475	CCTGGAGAGGGCGTGGGCAGTTCGTGGACCCGGGTCCCTTCCTGGAGAGGACGTGGGCAG	416
Qy	529	--CGAGCTGCCCCACGTCTCTCCAGGAAGGGACCCGGG--TCACGAACTGCCCCAGCGCT	584
Db	415	CTCATGAACCCGGGGTCCCTTCCTGGAGAGGGCGTGGGCAGCTCGTGAACCCGGGTGTCCC	356
Qy	585	CTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCCAGCCCTCTCCAGGAAGGGACCCCGG	644
Db	355	CTCCTGGAGAGGACGTGGGCAGCTCGTGAACCCGGGGTCCCTTCCTGGAGAGGACGTGGG	296
Qy	645	GTTACGAGCTGCCCCACGTCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCCAGT	704
Db	295	CAGTTCGTGGACCCGGGGTCCCTTCCTGGAGAGGACGTGGGCAGCTCGTGGACCCGGGGT	236
Qy	705	CCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCCAGCCCTCTCCAGGAGGGGACAC	764
Db	235	CCCTTCCTGGAGAGGACGTGGGCAGCTCGTGAACCCGGGGTCCCTTCCTGGAGAGGACGT	176
Qy	765	CGGGTTCACGAGCTGCCCCACGTCTCTCCAGGAAGGGACCCGGGTACGAGCTG-CCCAC	823
Db	175	GGGCAGCTCGTGGACCCGGGGTCCCTTCCTGCAGAGGACGTGGCCAGCTCGTGGACCCGG	116
Qy	824	GTCCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCCAGCACTTTC	872
Db	115	GTCCTTTCCTGGAGAGGACGTGGGCAGCTCGTGGACCCGGGTCCCTTCC	67

RESULT 7

US-10-743-704-6/c

; Sequence 6, Application US/10743704

; GENERAL INFORMATION:

; APPLICANT: KEITH, TIM

; APPLICANT: LITTLE, RANDALL D.

; APPLICANT: EERDEWEGH, PAUL VAN

; APPLICANT: DUPUIS, JOSEE

; APPLICANT: DEL MASTRO, RICHARD L.

; APPLICANT: SIMON, JASON

; APPLICANT: ALLEN, KRISTINA

; APPLICANT: PANDIT, SUNIL

; TITLE OF INVENTION: NOVEL HUMAN GENES RELATING TO RESPIRATORY DISEASES AND OBESITY

; FILE REFERENCE: 2976-4037

; CURRENT APPLICATION NUMBER: US/10/743,704

; CURRENT FILING DATE: 2003-12-22

; PRIOR APPLICATION NUMBER: US/09/627,465  
 ; PRIOR FILING DATE: 2000-07-28  
 ; PRIOR APPLICATION NUMBER: 60/211,749  
 ; PRIOR FILING DATE: 2000-06-14  
 ; PRIOR APPLICATION NUMBER: 60/146,336  
 ; PRIOR FILING DATE: 1999-07-30  
 ; NUMBER OF SEQ ID NOS: 51  
 ; SOFTWARE: PatentIn Ver 2.1  
 ; SEQ ID NO 6  
 ; LENGTH: 1576  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapiens  
 ; FEATURE:  
 ; NAME/KEY: CDS  
 ; LOCATION: (3)..(1190)  
 US-10-743-704-6

Query Match 9.3%; Score 130; DB 1; Length 1576;  
 Best Local Similarity 51.7%; Pred. No. 4.6;  
 Matches 429; Conservative 0; Mismatches 390; Indels 10; Gaps 6;

Qy	52	CCCACGCCCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAG	111
Db	893	CCGGGGTCCCTTCCTGGAAAGTGCGTGGGCAGCTCGTGAACCCGGTGTCCCTCCTGGAG	834
Qy	112	GGGACACCGGGTTCATGAGCTGCCCACGCCCTTTCCAGGAAGGGACCCCGGGTTCACGAG	171
Db	833	AGGACGTGGGCAGCTCGTG-GACCCGGGTCCCTTCCTGGAGAGGACGTGGGCAGCTCGTG	775
Qy	172	CTGCCCACGTCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAG	231
Db	774	AACCCGGTGTCCCTCCTGGAGAGGGCGTGGGCAGCTCGTGAACCCGGTGTCCCTCCTG	715
Qy	232	GAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCCGGG--TCAC	289
Db	714	GAGAGGACGTGGGCAGCTCGTGAACCCGGTGTCCCTCCTGGAGAGGACGTGGGCAGCTC	655
Qy	290	GAAGTGGCCACGTCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTC	349
Db	654	GTGAACCCGGGTCCCTTCCTGGAGAGGGCGTGGGCAGCTCGTGAACCCGGTGTCCCTC	595
Qy	350	CAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCCGGGT	409
Db	594	CTGGAGAGCGCGTGGGCAGTTCGTG-GACCCGGGTCCCTTCCTGGAGAGGACGTGGGCAG	536
Qy	410	CATGAGCTGCCCACGTCTCTCCAGGAAGGGACCCGGGTACGAACTGCCCACGCCCTCT	469
Db	535	CTCGTGGACCCGGGTCCCTTCCCGTTGACGACGTGGGCAGCTCGTGGACCCGGGTCCCT	476
Qy	470	CCAGGAGGGGACCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCCGGGTCA-	528
Db	475	CCTGGAGAGGGCGTGGGCAGTTCGTGGACCCGGGTCCCTTCCTGGAGAGGACGTGGGCAG	416
Qy	529	--CGAGCTGCCCACGTCTCTCCAGGAAGGGACCCGGG--TCACGAACTGCCCACGCGCT	584
Db	415	CTCATGAACCCGGGTCCCTTCCTGGAGAGGGCGTGGGCAGCTCGTGAACCCGGTGTCCC	356



Qy 585 CTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCCGG 644  
 |||| |||| |||| || || || || || || || || || || ||  
 Db 355 CTCCTGGAGAGGACGTGGGCAGCTCGTGAACCCGGGGTCCCTTCCTGGAGAGGACGTGGG 296  
 Qy 645 GTTCACGAGCTGCCCACGTCCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGT 704  
 || | || |||| |||| |||| |||| || || || || || ||  
 Db 295 CAGTTCGTGGACCCGGGGTCCCTTCCTGGAGAGGACGTGGGCAGCTCGTGGACCCGGGGT 236  
 Qy 705 CCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAGGGGACAC 764  
 || |||| |||| |||| || || || || || || || || || ||  
 Db 235 CCCTTCCTGGAGAGGACGTGGGCAGCTCGTGAACCCGGGGTCCCTTCCTGGAGAGGACGT 176  
 Qy 765 CGGGTTCACGAGCTGCCCACGTCCTCTCCAGGAAGGGACCCGGGTCACGAGCTG-CCCAC 823  
 || || || || || || || || || || || || || || || ||  
 Db 175 GGGCAGCTCGTGGACCCGGGGTCCCTTCCTGCAGAGGACGTGGCCAGCTCGTGGACCCGG 116  
 Qy 824 GTCCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCACTTTC 872  
 |||| |||| |||| |||| || || || || || || || || ||  
 Db 115 GTCCTTTCCTGGAGAGGACGTGGGCAGCTCGTGGACCCGGGTCCCTTCC 67

RESULT 8

US-10-743-704-2/c

; Sequence 2, Application US/10743704

; GENERAL INFORMATION:

; APPLICANT: KEITH, TIM

; APPLICANT: LITTLE, RANDALL D.

; APPLICANT: EERDEWEGH, PAUL VAN

; APPLICANT: DUPUIS, JOSEE

; APPLICANT: DEL MASTRO, RICHARD L.

; APPLICANT: SIMON, JASON

; APPLICANT: ALLEN, KRISTINA

; APPLICANT: PANDIT, SUNIL

; TITLE OF INVENTION: NOVEL HUMAN GENES RELATING TO RESPIRATORY DISEASES AND OBESITY

; FILE REFERENCE: 2976-4037

; CURRENT APPLICATION NUMBER: US/10/743,704

; CURRENT FILING DATE: 2003-12-22

; PRIOR APPLICATION NUMBER: US/09/627,465

; PRIOR FILING DATE: 2000-07-28

; PRIOR APPLICATION NUMBER: 60/211,749

; PRIOR FILING DATE: 2000-06-14

; PRIOR APPLICATION NUMBER: 60/146,336

; PRIOR FILING DATE: 1999-07-30

; NUMBER OF SEQ ID NOS: 51

; SOFTWARE: PatentIn Ver 2.1

; SEQ ID NO 2

; LENGTH: 1581

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: CDS

; LOCATION: (3)..(1307)

US-10-743-704-2

Query Match 9.3%; Score 130; DB 1; Length 1581;

Best Local Similarity 51.7%; Pred. No. 4.6;

Matches 429; Conservative 0; Mismatches 390; Indels 10; Gaps 6;

```
Qy      52 CCCACGCCCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAG 111
      ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||
Db      893 CCGGGGTCCCTTCTGGAAGTGCCTGGGCAGCTCGTGAACCCGGTGTCCCTCTCTGGAG 834

Qy     112 GGGACACCGGGTTCATGAGCTGCCCACGCCCTTTCCAGGAAGGGACCCCGGGTTCACGAG 171
      ||||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||
Db     833 AGGACGTGGGCAGCTCGTG-GACCCGGGTCCCTTCTCTGGAGAGGACGTGGGCAGCTCGTG 775

Qy     172 CTGCCCACGTCTCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAG 231
      ||  ||||  ||||  ||||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||
Db     774 AACCCGGTGTCCCTCTCTGGAGAGGGCGTGGGCAGCTCGTGAACCCGGTGTCCCTCTCTG 715

Qy     232 GAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCTCCAGGAAGGGACCCGGG--TCAC 289
      ||  ||||  ||  ||  ||  ||  ||  ||||  ||||  ||||  ||||  ||  ||
Db     714 GAGAGGACGTGGGCAGCTCGTGAACCCGGTGTCCCTCTCTGGAGAGGACGTGGGCAGCTC 655

Qy     290 GAACTGCCCACGTCTCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTC 349
      |  ||  ||||  ||||  ||||  ||  ||  ||  ||  ||  ||  ||  ||||  ||||
Db     654 GTGAACCCGGGGTCCCTTCTCTGGAGAGGGCGTGGGCAGCTCGTGAACCCGGTGTCCCTC 595

Qy     350 CAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCCGGGT 409
      |  ||||  |  |  ||  ||||  ||  ||  ||  ||  ||  ||  ||  ||  ||
Db     594 CTGGAGAGCGCGTGGGCAGTTCTGTG-GACCCGGGTCCCTTCTCTGGAGAGGACGTGGGCAG 536

Qy     410 CATGAGCTGCCCACGTCTCTCTCCAGGAAGGGACCCGGGTACGAACTGCCCACGCCCTCT 469
      |  |  ||  ||  ||||  ||  ||  ||  ||  ||  ||  ||  ||||  ||||
Db     535 CTCGTGGACCCGGGTCCCTTCCCGTTGACGACGTGGGCAGCTCGTGGACCCGGGTCCCT 476

Qy     470 CCAGGAGGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCCCGGGTCA- 528
      ||  ||||  ||  ||  ||||  ||  ||  ||  ||  ||  ||  ||  ||  ||
Db     475 CCTGGAGAGGGCGTGGGCAGTTCTGTGACCCGGGTCCCTTCTCTGGAGAGGACGTGGGCAG 416

Qy     529 --CGAGCTGCCCACGTCTCTCTCCAGGAAGGGACCCGGG--TCACGAACTGCCCACGCGCT 584
      |  |  ||  ||||  ||||  ||||  ||  ||  ||  ||  ||  ||  ||  ||
Db     415 CTCATGAACCCGGGGTCCCTTCTCTGGAGAGGGCGTGGGCAGCTCGTGAACCCGGTGTCCC 356

Qy     585 CTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCCGG 644
      ||||  ||||  ||||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||
Db     355 CTCCTGGAGAGGACGTGGGCAGCTCGTGAACCCGGGGTCCCTTCTCTGGAGAGGACGTGGG 296

Qy     645 GTTACGAGCTGCCCACGTCTCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGT 704
      ||  ||  ||  ||||  ||||  ||||  ||||  ||  ||  ||  ||  ||
Db     295 CAGTTCGTGGACCCGGGGTCCCTTCTCTGGAGAGGACGTGGGCAGCTCGTGGACCCGGGGT 236

Qy     705 CCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAGGGGACAC 764
      ||  ||||  ||||  ||||  ||  ||  ||  ||  ||  ||  ||  ||  ||
Db     235 CCCTTCTCTGGAGAGGACGTGGGCAGCTCGTGAACCCGGGGTCCCTTCTCTGGAGAGGACGT 176

Qy     765 CGGGTTCACGAGCTGCCCACGTCTCTCTCCAGGAAGGGACCCGGGTACGAGCTG-CCCAC 823
      ||  ||  ||  ||  ||  ||||  ||||  ||  ||  ||||  ||  ||  ||
Db     175 GGGCAGCTCGTGGACCCGGGGTCCCTTCTCTGCAGAGGACGTGGCCAGCTCGTGGACCCGG 116

Qy     824 GTCCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCACTTTC 872
      ||||  ||||  ||||  ||||  ||  ||  ||  ||  ||  ||  ||  ||
Db     115 GTCCTTCTCTGGAGAGGACGTGGGCAGCTCGTGGACCCGGGTCCCTTCC 67
```

RESULT 9

US-10-743-704-10/c

; Sequence 10, Application US/10743704

; GENERAL INFORMATION:

; APPLICANT: KEITH, TIM

; APPLICANT: LITTLE, RANDALL D.

; APPLICANT: EERDEWEGH, PAUL VAN

; APPLICANT: DUPUIS, JOSEE

; APPLICANT: DEL MASTRO, RICHARD L.

; APPLICANT: SIMON, JASON

; APPLICANT: ALLEN, KRISTINA

; APPLICANT: PANDIT, SUNIL

; TITLE OF INVENTION: NOVEL HUMAN GENES RELATING TO RESPIRATORY DISEASES AND OBESITY

; FILE REFERENCE: 2976-4037

; CURRENT APPLICATION NUMBER: US/10/743,704

; CURRENT FILING DATE: 2003-12-22

; PRIOR APPLICATION NUMBER: US/09/627,465

; PRIOR FILING DATE: 2000-07-28

; PRIOR APPLICATION NUMBER: 60/211,749

; PRIOR FILING DATE: 2000-06-14

; PRIOR APPLICATION NUMBER: 60/146,336

; PRIOR FILING DATE: 1999-07-30

; NUMBER OF SEQ ID NOS: 51

; SOFTWARE: PatentIn Ver 2.1

; SEQ ID NO 10

; LENGTH: 1744

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: CDS

; LOCATION: (3)..(1349)

US-10-743-704-10

Query Match 9.3%; Score 130; DB 1; Length 1744;

Best Local Similarity 51.7%; Pred. No. 4.2;

Matches 429; Conservative 0; Mismatches 390; Indels 10; Gaps 6;

```

Qy      52 CCCACGCCCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAG 111
      ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||
Db      893 CCGGGGTCCCTTCCTGGAAAGTGCGTGCGGTCAGCTCGTGAACCCGGTGTCCCTCCTGGAG 834

Qy      112 GGGACACCGGGTTCATGAGCTGCCCACGCCCTTTCCAGGAAGGGACCCCGGGTTCACGAG 171
      ||||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||
Db      833 AGGACGTGGGCAGCTCGTG-GACCCGGGTCCCTTCCTGGAGAGGACGTGGGCAGCTCGTG 775

Qy      172 CTGCCCACGTCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAG 231
      ||  ||||  ||||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||
Db      774 AACCCGGTGTCCCTCCTGGAGAGGGCGTGGGCAGCTCGTGAACCCGGTGTCCCTCCTG 715

Qy      232 GAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCCGGG--TCAC 289
      ||  ||||  ||  ||  ||  ||  ||  ||||  ||||  ||  ||  ||  ||
Db      714 GAGAGGACGTGGGCAGCTCGTGAACCCGGTGTCCCTCCTGGAGAGGACGTGGGCAGCTC 655

Qy      290 GAACTGCCCACGTCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTC 349

```

```

      | | | | | | | | | | | | | | | | | | | | | |
Db    654 GTGAACCCGGGGTCCCTTCCTGGAGAGGGCGTGGGCAGCTCGTGAACCCGGTGTCCCTC 595

Qy    350 CAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCGGGTT 409
      | | | | | | | | | | | | | | | | | | | | | |
Db    594 CTGGAGAGCGCGTGGGCAGTTCGTG-GACCCGGGTCCCTTCCTGGAGAGGACGTGGGCAG 536

Qy    410 CATGAGCTGCCCACGTCTCTCCAGGAAGGGACCCGGGTACGAACTGCCCACGCCCTCT 469
      | | | | | | | | | | | | | | | | | | | | | |
Db    535 CTCGTGGACCCGGGTCCCTTCCCGTTGACGACGTGGGCAGCTCGTGGACCCGGGTCCCT 476

Qy    470 CCAGGAGGGGACCCGGGTACAGAGCTGCCCACGTCTCTCCAGGAAGGGACCCGGGTCA- 528
      | | | | | | | | | | | | | | | | | | | | | |
Db    475 CCTGGAGAGGGCGTGGGCAGTTCGTGGACCCGGGTCCCTTCCTGGAGAGGACGTGGGCAG 416

Qy    529 --CGAGCTGCCCACGTCTCTCCAGGAAGGGACCCGGG--TCACGAACTGCCCACGCGCT 584
      | | | | | | | | | | | | | | | | | | | | | |
Db    415 CTCATGAACCCGGGGTCCCTTCCTGGAGAGGGCGTGGGCAGCTCGTGAACCCGGTGTCCC 356

Qy    585 CTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCCGG 644
      | | | | | | | | | | | | | | | | | | | | | |
Db    355 CTCCTGGAGAGGACGTGGGCAGCTCGTGAACCCGGGGTCCCTTCCTGGAGAGGACGTGGG 296

Qy    645 GTTCACGAGCTGCCCACGTCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGT 704
      | | | | | | | | | | | | | | | | | | | | | |
Db    295 CAGTTCGTGGACCCGGGGTCCCTTCCTGGAGAGGACGTGGGCAGCTCGTGGACCCGGGGT 236

Qy    705 CCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAGGGGACAC 764
      | | | | | | | | | | | | | | | | | | | | | |
Db    235 CCCTTCCTGGAGAGGACGTGGGCAGCTCGTGAACCCGGGGTCCCTTCCTGGAGAGGACGT 176

Qy    765 CGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCCGGGTACGAGCTG-CCCAC 823
      | | | | | | | | | | | | | | | | | | | | | |
Db    175 GGGCAGCTCGTGGACCCGGGGTCCCTTCCTGCAGAGGACGTGGCCAGCTCGTGGACCCGG 116

Qy    824 GTCCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCACTTTC 872
      | | | | | | | | | | | | | | | | | | | | | |
Db    115 GTCCTTTCCTGGAGAGGACGTGGGCAGCTCGTGGACCCGGGTCCCTTC 67

```

RESULT 10

US-10-743-704-8/c

; Sequence 8, Application US/10743704

; GENERAL INFORMATION:

; APPLICANT: KEITH, TIM

; APPLICANT: LITTLE, RANDALL D.

; APPLICANT: EERDEWEGH, PAUL VAN

; APPLICANT: DUPUIS, JOSEE

; APPLICANT: DEL MASTRO, RICHARD L.

; APPLICANT: SIMON, JASON

; APPLICANT: ALLEN, KRISTINA

; APPLICANT: PANDIT, SUNIL

; TITLE OF INVENTION: NOVEL HUMAN GENES RELATING TO RESPIRATORY DISEASES AND OBESITY

; FILE REFERENCE: 2976-4037

; CURRENT APPLICATION NUMBER: US/10/743,704

; CURRENT FILING DATE: 2003-12-22

; PRIOR APPLICATION NUMBER: US/09/627,465  
; PRIOR FILING DATE: 2000-07-28  
; PRIOR APPLICATION NUMBER: 60/211,749  
; PRIOR FILING DATE: 2000-06-14  
; PRIOR APPLICATION NUMBER: 60/146,336  
; PRIOR FILING DATE: 1999-07-30  
; NUMBER OF SEQ ID NOS: 51  
; SOFTWARE: PatentIn Ver 2.1  
; SEQ ID NO 8  
; LENGTH: 2010  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: (3)..(1244)  
US-10-743-704-8

Query Match 9.3%; Score 130; DB 1; Length 2010;  
Best Local Similarity 51.7%; Pred. No. 3.6;  
Matches 429; Conservative 0; Mismatches 390; Indels 10; Gaps 6;

```
Qy      52 CCCACGCCCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAG 111
      || | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      893 CCGGGGTCCCTTCTCGAAAGTGCCTGGGCAGCTCGTGAACCCGGTGTCCCTCTCGGAG 834

Qy      112 GGGACACCGGGTTCATGAGCTGCCCACGCCCTTTCCAGGAAGGGACCCCGGGTTCACGAG 171
      || | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      833 AGGACGTGGGCAGCTCGTG-GACCCGGGTCCCTTCTCGGAGAGGACGTGGGCAGCTCGTG 775

Qy      172 CTGCCCACGTCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAG 231
      || | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      774 AACCCGGTGTCCCTCTCGGAGAGGGCGTGGGCAGCTCGTGAACCCGGTGTCCCTCTCTG 715

Qy      232 GAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCCGGG--TCAC 289
      || | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      714 GAGAGGACGTGGGCAGCTCGTGAACCCGGTGTCCCTCTCGGAGAGGACGTGGGCAGCTC 655

Qy      290 GAACTGCCCACGTCTCTCCAGGAAGGGACCCCGGGTTCACGAGCTGCCCACGTCTCTCTC 349
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      654 GTGAACCCGGGTCCCTTCTCGGAGAGGGCGTGGGCAGCTCGTGAACCCGGTGTCCCTCTC 595

Qy      350 CAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCCGGGT 409
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      594 CTGGAGAGCGCGTGGGCAGTTCTG-GACCCGGGTCCCTTCTCGGAGAGGACGTGGGCAG 536

Qy      410 CATGAGCTGCCCACGTCTCTCCAGGAAGGGACCCGGGTTCACGAAGTCCCACGCCCTCT 469
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      535 CTCGTGGACCCGGGTCCCTTCCCGTTGACGACGTGGGCAGCTCGTGGACCCGGGTCCCT 476

Qy      470 CCAGGAGGGGACCCGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCCGGGTCA- 528
      || | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      475 CCTGGAGAGGGCGTGGGCAGTTCTGGAACCCGGGTCCCTTCTCGGAGAGGACGTGGGCAG 416

Qy      529 --CGAGCTGCCCACGTCTCTCCAGGAAGGGACCCGGG--TCACGAAGTCCCACGCGCT 584
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      415 CTCATGAACCCGGGTCCCTTCTCGGAGAGGGCGTGGGCAGCTCGTGAACCCGGTGTCCC 356
```

Qy 585 CTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAAGGGACCCCGG 644  
 |||| |||| |||| || || || || || || || || || || || ||  
 Db 355 CTCCTGGAGAGGACGTGGGCAGCTCGTGAACCCGGGGTCCCTTCCTGGAGAGGACGTGGG 296

Qy 645 GTTCACGAGCTGCCCACGTCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGT 704  
 || | || |||| || |||| |||| || || || || || || || ||  
 Db 295 CAGTTCGTGGACCCGGGGTCCCTTCCTGGAGAGGACGTGGGCAGCTCGTGGACCCGGGGT 236

Qy 705 CCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCCCTCTCCAGGAGGGGACAC 764  
 || |||| |||| |||| || || || || || || || || || || ||  
 Db 235 CCCTTCCTGGAGAGGACGTGGGCAGCTCGTGAACCCGGGGTCCCTTCCTGGAGAGGACGT 176

Qy 765 CGGGTTCACGAGCTGCCCACGTCTCTCCAGGAAGGGACCCGGGTACGAGCTG-CCCAC 823  
 || | || | || |||| |||| || |||| || || || || || || ||  
 Db 175 GGGCAGCTCGTGGACCCGGGGTCCCTTCCTGCAGAGGACGTGGCCAGCTCGTGGACCCGG 116

Qy 824 GTCCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCCACGCACTTTC 872  
 |||| |||| |||| |||| || || || || || || || || || ||  
 Db 115 GTCCTTTCCTGGAGAGGACGTGGGCAGCTCGTGGACCCGGGTCCCTTCC 67

Search completed: October 24, 2006, 13:12:57  
 Job time : 3 secs

> O <  
| O IntelliGenetics  
> O <

GENALIGN - Multiple Sequence Alignment Program  
Release 5.4

Mon 23 Oct 106 16:32:10-PDT

#### Solution Parameters:

Nucleic Alphabet = Identity  
Output line length = 80  
Compress = Off  
Histogram = Off  
Randomization = Off  
  
AMINO-Res-length = 2  
DEletion-weight = 5.00  
Length-factor = 0  
Matching-weight = 1.00  
NUCLEIC-Res-length = 4  
Spread-factor = 50

#### Clustered order of selected sequences:

1. US-10-743-704-1 (1-10304)  
3. US-10-743-704-4 (1-1441)  
2. US-10-743-704-2 (1-1581)  
4. US-10-743-704-6 (1-1576)  
5. US-10-743-704-10 (1-1744)  
5. US-10-743-704-8 (1-2010)

#### Needleman-Wunsch Alignment: (listed in Clustered order)

```

US-10-743-1 1 cggcgctgtatattcttcatagagagctcagaacgctgctgaatctgctcgatat
US-10-743-4 1 TCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
US-10-743-2 1 TCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
US-10-743-6 1 TCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
US-10-743-10 1 TCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
US-10-743-8 1 TCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
consensus 1 TCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT

US-10-743-62 1 atagAGatcttttAtCactGagtAgatagaaCgtACatgaatgtacGaaAcAGtcCagacGag
US-10-743-4 1 TCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
US-10-743-2 1 TCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
US-10-743-6 1 TCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
US-10-743-10 1 TCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
US-10-743-8 1 TCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
consensus 1 TCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT

US-10-743-123 1 AacttgactaggataagataGacaGtAccaaCTaatGagaChagAgaGggaAtcataTa
US-10-743-123 1 CACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
US-10-743-123 1 CACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT

```

```

US-10-743-123 CACGAGCTGCGCACGTCCTCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
US-10-743-123 CACGAGCTGCGCACGTCCTCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
US-10-743-123 CACGAGCTGCGCACGTCCTCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
consensus CACGAGCTGCGCACGTCCTCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT

US-10-743-184 gaatcatgtatGtCtgaGtCtTagcgagtGtGcaCAtGatCaCaagcGAAAtacAgaCtatGa
US-10-743-184 TCCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGT
US-10-743-184 TCCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGT
US-10-743-184 TCCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGT
US-10-743-184 TCCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGT
US-10-743-184 TCCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGT
US-10-743-184 TCCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGT
consensus TCCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGT

US-10-743-245 gaAgagGtaGaaatAaTaagtAnactGAGaaGAGaggtCaTatgtacAtacaaatCagtaa
US-10-743-245 CCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
US-10-743-245 CCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
US-10-743-245 CCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
US-10-743-245 CCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
US-10-743-245 CCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
US-10-743-245 CCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT
consensus CCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCGT

US-10-743-306 agCaAtagAaatGaatatacaTtataagcCacagttacagaaTTagcctAattttAaacacca
US-10-743-306 CTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGT
US-10-743-306 CTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGT
US-10-743-306 CTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGT
US-10-743-306 CTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGT
US-10-743-306 CTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGT
US-10-743-306 CTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGT
consensus CTCAGGAAGGACCCCGGGTTCACGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGT

US-10-743-367 TggcaagcagGttatatCaaaCatagaagAGtaAaCtCtatcgaccatGggtaggAacgaa
US-10-743-367 TTCAGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCATAGCTGCCACAGTCC
US-10-743-367 TTCAGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCATAGCTGCCACAGTCC
US-10-743-367 TTCAGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCATAGCTGCCACAGTCC
US-10-743-367 TTCAGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCATAGCTGCCACAGTCC
US-10-743-367 TTCAGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCATAGCTGCCACAGTCC
US-10-743-367 TTCAGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCATAGCTGCCACAGTCC
US-10-743-367 TTCAGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCATAGCTGCCACAGTCC
consensus TTCAGAGTGCCTCCACGTCCTTCAGGAAGGACCCCGGGTTCATAGCTGCCACAGTCC

US-10-743-428 TaaagcGtCgaGaaGaaCaafTaagaatGcgtgttAaaCagcaatacaagaGaatagCacca
US-10-743-428 TCTCCAGGAAGGACCCCGGGTTCACGAACTGCCCCACGCCCTCTCTCCAGGAGGACCCCGGGT

```

```
US-10-743- 428 TCTCCAGGAAGGACCCGGGTCCACGAACTGCCCAAGCCCTCTCCAGGAGGGGACCCGGGT
US-10-743- 428 TCTCCAGGAAGGACCCGGGTCCACGAACTGCCCAAGCCCTCTCCAGGAGGGGACCCGGGT
US-10-743- 428 TCTCCAGGAAGGACCCGGGTCCACGAACTGCCCAAGCCCTCTCCAGGAGGGGACCCGGGT
US-10-743- 428 TCTCCAGGAAGGACCCGGGTCCACGAACTGCCCAAGCCCTCTCCAGGAGGGGACCCGGGT
consensus TctccagGaaGgGaccgggtTccacgaaCtgcccAogCctctccaggagGggaaccGgggt
US-10-743- 489 CtaagacagcCaaAGeGtCAcCGGgAaGtAgggaAGagggcacctCacaaggaGaggaa
US-10-743- 489 CACAGAGCTGCCACAGTCTGTCACAGGAGAGGACCCGGGTCCACGAGCTGCCACAGTCTCTC
US-10-743- 489 CCAAGAGCTGCCACAGTCTGTCACAGGAGAGGACCCGGGTCCACGAGCTGCCACAGTCTCTC
US-10-743- 489 CCAAGAGCTGCCACAGTCTGTCACAGGAGAGGACCCGGGTCCACGAGCTGCCACAGTCTCTC
US-10-743- 489 CCAAGAGCTGCCACAGTCTGTCACAGGAGAGGACCCGGGTCCACGAGCTGCCACAGTCTCTC
US-10-743- 489 CCAAGAGCTGCCACAGTCTGTCACAGGAGAGGACCCGGGTCCACGAGCTGCCACAGTCTCTC
US-10-743- 489 CCAAGAGCTGCCACAGTCTGTCACAGGAGAGGACCCGGGTCCACGAGCTGCCACAGTCTCTC
consensus CcacgagctgCCcAcAgC-GtCAaCGGgAGgGaccggGtccacgagCtgcccacGtccctc
US-10-743- 550 agggcagtcctgatTTTGAaAtttcagtgaaAGacagtggtttccccGGAGgAGctT'a
US-10-743- 550 TCCAGGAAGGACCCGGGTCCAGAACTGCGCCACGCGCTCTCCAGGAGGGGACACCGGGTT
US-10-743- 550 TCCAGGAAGGACCCGGGTCCAGAACTGCGCCACGCGCTCTCCAGGAGGGGACACCGGGTT
US-10-743- 550 TCCAGGAAGGACCCGGGTCCAGAACTGCGCCACGCGCTCTCCAGGAGGGGACACCGGGTT
US-10-743- 550 TCCAGGAAGGACCCGGGTCCAGAACTGCGCCACGCGCTCTCCAGGAGGGGACACCGGGTT
US-10-743- 550 TCCAGGAAGGACCCGGGTCCAGAACTGCGCCACGCGCTCTCCAGGAGGGGACACCGGGTT
US-10-743- 550 TCCAGGAAGGACCCGGGTCCAGAACTGCGCCACGCGCTCTCCAGGAGGGGACACCGGGTT
consensus tccagggaagggaacccggGtccAcgaactgccAcGegctctccaggaggGgaCaCcgggTt
US-10-743- 611 gtgacCCGatcgaCtCTgaagAGGAcctgagggtaggggAttttttgGcCtgacCggc
US-10-743- 611 CACGAGTGCACAGCCCTCTCCAGGAAGGACCCCGGGTTCACGAGCTGCCACAGTCTCTC
US-10-743- 611 CACGAGTGCACAGCCCTCTCCAGGAAGGACCCCGGGTTCACGAGCTGCCACAGTCTCTC
US-10-743- 611 CACGAGTGCACAGCCCTCTCCAGGAAGGACCCCGGGTTCACGAGCTGCCACAGTCTCTC
US-10-743- 611 CACGAGTGCACAGCCCTCTCCAGGAAGGACCCCGGGTTCACGAGCTGCCACAGTCTCTC
US-10-743- 611 CACGAGTGCACAGCCCTCTCCAGGAAGGACCCCGGGTTCACGAGCTGCCACAGTCTCTC
US-10-743- 611 CACGAGTGCACAGCCCTCTCCAGGAAGGACCCCGGGTTCACGAGCTGCCACAGTCTCTC
consensus cagagTgCccacGcCtctccAGGAagggaaccccgGgttcAcgagctGcCCacgtCctc
US-10-743- 672 ctatGctGaacGcCaccGggatTccaggGagaaAacaCggggCcccggttccaggagAc
US-10-743- 672 TCCAGGAGGGGACACCGGGTTCACGAGCTGCCACAGTCTCTCCAGGAGGGGACACCGGGT
US-10-743- 672 TCCAGGAGGGGACACCGGGTTCACGAGCTGCCACAGTCTCTCCAGGAGGGGACACCGGGT
US-10-743- 672 TCCAGGAGGGGACACCGGGTTCACGAGCTGCCACAGTCTCTCCAGGAGGGGACACCGGGT
US-10-743- 672 TCCAGGAGGGGACACCGGGTTCACGAGCTGCCACAGTCTCTCCAGGAGGGGACACCGGGT
US-10-743- 672 TCCAGGAGGGGACACCGGGTTCACGAGCTGCCACAGTCTCTCCAGGAGGGGACACCGGGT
US-10-743- 672 TCCAGGAGGGGACACCGGGTTCACGAGCTGCCACAGTCTCTCCAGGAGGGGACACCGGGT
US-10-743- 672 TCCAGGAGGGGACACCGGGTTCACGAGCTGCCACAGTCTCTCCAGGAGGGGACACCGGGT
consensus tccaGgaGgggaCaCcgGgtTtcAcgagctGccccAgtCctctCCagGagggggaacccGgtc
US-10-743- 733 agcCagGcCaCagcCctgaggaGggcAaaccCCACcCaGgcagGtGagaggAgcGcgc
```

```
US-10-743- 733 TCACGAGCTGCCACAGCCCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCACAGTCTCT
US-10-743- 733 TCACGAGCTGCCACAGCCCTCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCACAGTCTCT
US-10-743- 733 TCACGAGCTGCCACAGCCCTCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCACAGTCTCT
US-10-743- 733 TCACGAGCTGCCACAGCCCTCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCACAGTCTCT
US-10-743- 733 TCACGAGCTGCCACAGCCCTCTCTCCAGGAGGGGACACCGGGTTCACGAGCTGCCACAGTCTCT
consensus tCaGgAGtGcCcaGgcctctCcaGgAggggaACCCggGtTcaGgAGtgcctAcAGtCct
US-10-743- 794 CcaggcctgGGcCtGgGcGgCaggGgataagTggagCagagCCcGcScaaatCctaacGgG
US-10-743- 794 CTCAGGAAGGACCCGGGTCCACGAGCTGCCACAGTCTCTCTCCAGGAGGGGACACCGGGT
US-10-743- 794 CTCAGGAAGGACCCGGGTCCACGAGCTGCCACAGTCTCTCTCCAGGAGGGGACACCGGGT
US-10-743- 794 CTCAGGAAGGACCCGGGTCCACGAGCTGCCACAGTCTCTCTCCAGGAGGGGACACCGGGT
US-10-743- 794 CTCAGGAAGGACCCGGGTCCACGAGCTGCCACAGTCTCTCTCCAGGAGGGGACACCGGGT
US-10-743- 794 CTCAGGAAGGACCCGGGTCCACGAGCTGCCACAGTCTCTCTCCAGGAGGGGACACCGGGT
US-10-743- 794 CTCAGGAAGGACCCGGGTCCACGAGCTGCCACAGTCTCTCTCCAGGAGGGGACACCGGGT
US-10-743- 794 CTCAGGAAGGACCCGGGTCCACGAGCTGCCACAGTCTCTCTCCAGGAGGGGACACCGGGT
consensus CtcaggaaGGaCccGgGtCcAcGagctgccccagTcCctctCCagGaggggaCaacGgGt
US-10-743- 855 ggtgagcagtgagcCtGtGgCgAGtGGtCCgtttTggggGtTgtttgtCctgCag
US-10-743- 855 TCACGAGCTGCCACAGCACTTTCCAGGAAGGACCCCGGGTTCAGGTCTCTCTCCCGGCCCA
US-10-743- 855 TCACGAGCTGCCACAGCACTTTCCAGGAAGGACCCCGGGTTCAGGTCTCTCTCCCGGCCCA
US-10-743- 855 TCACGAGCTGCCACAGCACTTTCCAGGAAGGACCCCGGGTTCAGGTCTCTCTCCCGGCCCA
US-10-743- 855 TCACGAGCTGCCACAGCACTTTCCAGGAAGGACCCCGGGTTCAGGTCTCTCTCCCGGCCCA
US-10-743- 855 TCACGAGCTGCCACAGCACTTTCCAGGAAGGACCCCGGGTTCAGGTCTCTCTCCCGGCCCA
US-10-743- 855 TCACGAGCTGCCACAGCACTTTCCAGGAAGGACCCCGGGTTCAGGTCTCTCTCCCGGCCCA
consensus tcaGagctgccccGgcacTtTccaggAGgGgacCCcgggTtcaGgTcTcctgcCgGcCca
US-10-743- 916 CaaatgatgccGccctgAcggaAccAGtGcagctccACaagagctgcCcaagTCTcctcC
US-10-743- 916 CATCGTCCCTTTGTGTAAATCAGAAAGATGAGGAACAGGCCCTCTCTCTCTCCAGGC
US-10-743- 916 CATCGTCCCTTTGTGTAAATCAGAAAGATGAGGAACAGGCCCTCTCTCTCTCCAGGC
US-10-743- 916 CATCGTCCCTTTGTGTAAATCAGAAAGATGAGGAACAGGCCCTCTCTCTCTCCAGGC
US-10-743- 916 CATCGTCCCTTTGTGTAAATCAGAAAGATGAGGAACAGGCCCTCTCTCTCTCCAGGC
US-10-743- 916 CATCGTCCCTTTGTGTAAATCAGAAAGATGAGGAACAGGCCCTCTCTCTCTCCAGGC
US-10-743- 916 CATCGTCCCTTTGTGTAAATCAGAAAGATGAGGAACAGGCCCTCTCTCTCTCCAGGC
consensus CatcgtgccttTgtGTAAATCAGAAAGATGAGGAACAGGCCCTCTCTCTCTCCAGGC
US-10-743- 977 caGgaaggGacccccGGTCCacgagctgccccagTcctctcCaggaaggGaccgaagacCac
US-10-743- 977 AGCTTTTGTGGAGGGGCTGGATCTCCT G C GCA C CTT
US-10-743- 977 AGCTTTTGTGGAGGGGCTGGATCTCCT G C GCA C CTT
US-10-743- 977 AGCTTTTGTGGAGGGGCTGGATCTCCT G C GCA C CTT
US-10-743- 977 AGCTTTTGTGGAGGGGCTGGATCTCCT G C GCA C CTT
US-10-743- 977 AGCTTTTGTGGAGGGGCTGGATCTCCT G C GCA C CTT
US-10-743- 977 AGCTTTTGTGGAGGGGCTGGATCTCCT G C GCA C CTT
consensus agCcttTGGtgaGGGcTggatcctcct-c-g---cct---cC-ggcaggGgac-c-g--Ctt
```





```
consensus      tctttctctctccagctttattagggtatag-t-acaattcaggacggtgtgactcaaa
US-10-743- 1648 agctgccacagtcctctccaggaaggacccccggttcacgagctgccacgctcctctcca
US-10-743- 1116 TG G A CC TG G AGACAGGGTTTCT
US-10-743- 1218 ccttttctctctctccagctttattagggtatag-t-acaattcaggacggtgtgactcaaa
US-10-743- 1218 GGTATGAGCATCAACACCTGACACAGTA GGCATTGTGAATGAGTCCCAATTTGG
US-10-743- 1381 GGTATGAGCATCAACACCTGACACAGTA GGCATTGTGAATGAGTCCCAATTTGG
US-10-743- 1648 GGTATGAGCATCAACACCTGACACAGTA GGCATTGTGAATGAGTCCCAATTTGG
consensus      ggtatgagcatcaacaacctgacacagtcaccgcatgtgaaatgagtgctcccaaatTg-g
US-10-743- 1709 ggaagggaacCCGGTccaGgaGtgcCCagctCctctcCaggaagggaacCCgggtCcaC
US-10-743- 1138 CCTCATTTGGCAGGCTGGTCTGAACTCTCTGACCTCAGACGATCCACCTGCTCAGCTCC
US-10-743- 1279 CCTCATTTGGCAGGCTGGTCTGAACTCTCTGACCTCAGACGATCCACCTGCTCAGCTCC
US-10-743- 1277 CTAAATTAACACACCCATCACTTACATGTTACTTCTTCTGTTGAGTGAACACTAAAT T
US-10-743- 1440 CTAAATTAACACACCCATCACTTACATGTTACTTCTTCTGTTGAGTGAACACTAAAT T
US-10-743- 1707 CTAAATTAACACACCCATCACTTACATGTTACTTCTTCTGTTGAGTGAACACTAAAT T
consensus      ctaattaac-Ca--c-tcaCct-acat--ttac-tctttCtGtggtgaga-Cact-a-tc-
US-10-743- 1770 gaActgcccaGtctctCtccaggAGgAGccccgggttcAGagctGcCacgtCctctcc
US-10-743- 1199 CGAAGTGTGGGATTACAGGCACGACCTGTCGCCGGCCATCATTCCTTTTACTGTCTG
US-10-743- 1340 CGAAGTGTGGGATTACAGGCACGACCTGTCGCCGGCCATCATTCCTTTTACTGTCTG
US-10-743- 1337 TTAATATAGAGACACACA GCCTGGCAACATAGTGAACCCCT GTCTTACAAATATAA
US-10-743- 1500 TTAATATAGAGACACACA GCCTGGCAACATAGTGAACCCCT GTCTTACAAATATAA
US-10-743- 1767 TTAATATAGAGACACACA GCCTGGCAACATAGTGAACCCCT GTCTTACAAATATAA
consensus      tAaatagagg-cacaCaggcctg-GcaACataGtagacCctcgfc-Ctaca-a--taaa
US-10-743- 1831 AggAggGaCacCgGgtTcAcgagctgcCaAcgcccCtCtCcaggAGggacccccgggtTtca
US-10-743- 1260 ACTAATATGCTGCTGTGTGAATCCACGGCTAGAAACCCATCATTCAGTTGATGTCATGTG
US-10-743- 1401 ACTAATATGCTGCTGTGTGAATCCACGGCTAGAAACCCATCATTCAGTTGATGTCATGTG
US-10-743- 1396 AAAATTTATCTGAGCTGTGTGTGTCACACCTGTGTGCCAGTACTTGGGAAGCTGAGGCTG
US-10-743- 1559 AAAATTTATCTGAGCTGTGTGTGTCACACCTGTGTGCCAGTACTTGGGAAGCTGAGGCTG
US-10-743- 1826 AAAATTTATCTGAGCTGTGTGTGTCACACCTGTGTGCCAGTACTTGGGAAGCTGAGGCTG
consensus      AaaAtta-c-gg-cGtg-t-gtgcacacCt-tggtCcCa-ctaCt-Gggaagctgag-ctg
US-10-743- 1892 tGagctgcCcaCgtcctctctccAGgAagggacccccgggtccAcgAAcTgcCCacgcCctctcc
US-10-743- 1321 GGTTCCTTCTGCTATTGCTGTTATTAATGAACAGTCTGGAATAAACGTTCTGTGCACTCTT
US-10-743- 1462 GGTTCCTTCTGCTATTGCTGTTATTAATGAACAGTCTGGAATAAACGTTCTGTGCACTCTT
US-10-743- 1457 GAGAATCACTTGAACCTGGAGGGAGGAGTGTGGTGCATCTCCAGCTTGGGCGACAGAGG
US-10-743- 1620 GAGAATCACTTGAACCTGGAGGGAGGAGTGTGGTGCATCTCCAGCTTGGGCGACAGAGG
```

```
US-10-743- 1887 GAGATCACTTGAAGCTGGAGCGAGGTTGGGTGCACTCCAGCTTGGCGCACAGAGG
consensus      g-gaatcaCtt-agcctggga-gc-g-ggttgcGgtgca-tc-A-cct--ggaCagaggg
US-10-743- 1953 aGgagggggaCCgGgtccacgAgctgcccacgtcgtcaAcgggaaaggAcccgggtccAcg
US-10-743- 1382 GGGCATACCCCTAGAGTGGAACTCTCTGGTCAAAAAAATAA AAAAAAATAAATAA
US-10-743- 1523 GGGCATACCCCTAGAGTGGAACTCTCTGGTCAAAAAAATAA AAAAAAATAAATAA
US-10-743- 1518 AGCCCTATCTCAAAATAAATAAATAAAGGAC ACATTCTTATC AAAAAAATAAATAA
US-10-743- 1681 AGCCCTATCTCAAAATAAATAAATAAAGGAC ACATTCTTATC AAAAAAATAAATAA
US-10-743- 1948 AGCCCTATCTCAAAATAAATAAATAAAGGAC ACATTCTTATC AAAAAAATAAATAA
consensus      aGccctatC-ca--ataaatAaataaaggac-acat--ttatcaaaaaaataaAaa
US-10-743- 2014 Agctgccacagtcctctccaggaaaggacccgggtccacgaactgcccacgctctccag
US-10-743- 1438 AAAAA
US-10-743- 1578 AAAAA
US-10-743- 1573 AAAAA
US-10-743- 1741 AAAAA
US-10-743- 2007 AAAAA
consensus      Aaaagccacagtcctctccaggaaaggacccgggtccacgaactgcccacgctctccag
US-10-743- 2075 gagggacacccgggttcacgagctgcccacgctctccaggaaaggacccgggttcacg
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      gagggacacccgggttcacgagctgcccacgctctccaggaaaggacccgggttcacg
US-10-743- 2136 agctgccacagtcctctccaggaaaggacacacgggttcacgagctgcccacgctctccca
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      agctgccacagtcctctccaggaaaggacacacgggttcacgagctgcccacgctctccca
US-10-743- 2197 ggaggagacacgggttcacgagctgcccacgctctccaggaaaggacacacgggttcac
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
```

US-10-743- 1745  
US-10-743- 2011  
consensus ggaggggacaccgggttcacgagctgcccaagcgcctctccaggaggagggacacccgggttcac  
US-10-743- 2258 gagctgcccacagctcctctccaggaaggaccgggtccacgagctgcccaagctcctctcca  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus gagctgcccacagctcctctccaggaaggaccgggtccacgagctgcccaagctcctctcca  
US-10-743- 2319 ggaggggacaccgggttcacgagctgcccaagcgccttccaggaaggaccgggttcag  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus ggaggggacaccgggttcacgagctgcccaagcgccttccaggaaggaccgggttcag  
US-10-743- 2380 gtctctgccggcccaacatcgtgcctttgtgtaaatcagaagaagatgaggaacaggccc  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus gtctctgccggcccaacatcgtgcctttgtgtaaatcagaagaagatgaggaacaggccc  
US-10-743- 2441 tectctctccaggcaggctttggtggaggggctggatctcctgcgcgcaaccttccctggc  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus tectctctccaggcaggctttggtggaggggctggatctcctgcgcgcaaccttccctggc  
US-10-743- 2502 agggcaccctgtgcttgagccccagaactgcaggcgccgcagagaagggtccatgatg  
US-10-743- 1442  
US-10-743- 1582

US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus agggcaccctgtgcttgagccccagaactgcaggcgccgcagagaagggtccatgatg  
US-10-743- 2563 gcgcctcggtagcgagccttggacctgcccccatggacctggacctgggtgaggactccagacct  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus gcgcctcggtagcgagccttggacctgcccccatggacctggacctgggtgaggactccagacct  
US-10-743- 2624 tccccgggtccagctgctctccctaagcgcctcaccccttccctcgggcagggggcagtgg  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus tccccgggtccagctgctctccctaagcgcctcaccccttccctcgggcagggggcagtgg  
US-10-743- 2685 acgagggttcggtccctccaggggatgctcccaaacccctgccaggacttggcagatccgg  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus acgagggttcggtccctccaggggatgctcccaaacccctgccaggacttggcagatccgg  
US-10-743- 2746 cctctcatcttggcagctagatggtgggacgggagatcgtggtggcttaatttgcattt  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus cctctcatcttggcagctagatggtgggacgggagatcgtggtggcttaatttgcattt  
US-10-743- 2807 ctctgatgactgatgatttcagcatctctcatatgtttgctggctttggggatagat  
US-10-743- 1442

US-10-743- 1582		US-10-743- 1442	
US-10-743- 1577		US-10-743- 1582	
US-10-743- 1745		US-10-743- 1577	
US-10-743- 2011		US-10-743- 1745	
consensus	ctctgatgactgatgatttcgagcatctcttcatatgtttgctggccttggggatagagat	consensus	tggcctggaccctcgctgagccctcagggctctgcgccactcaaccagcgcttgt
US-10-743- 2868	atttcttccctaaagcaaaacttgattatgtcatttctgcttccaagatgccagtgatgcctg	US-10-743- 3173	tccgcaggaacctcccggctcttcccactcgggaaaggagctctgggcatggaggtcgg
US-10-743- 1442		US-10-743- 1442	
US-10-743- 1582		US-10-743- 1582	
US-10-743- 1577		US-10-743- 1577	
US-10-743- 1745		US-10-743- 1745	
US-10-743- 2011		US-10-743- 2011	
consensus	atttcttccctaaagcaaaacttgattatgtcatttctgcttccaagatgccagtgatgcctg	consensus	tccgcaggaacctcccggctcttcccactcgggaaaggagctctgggcatggaggtcgg
US-10-743- 2929	aggctcgcagggcagtgcatatcgctaccgcctggccgctcaggagcctgtgcttgacccc	US-10-743- 3234	ccaggcccatcccgtaacctggcccttcttctgcttcttctgcttctgctcactgccccggg
US-10-743- 1442		US-10-743- 1442	
US-10-743- 1582		US-10-743- 1582	
US-10-743- 1577		US-10-743- 1577	
US-10-743- 1745		US-10-743- 1745	
US-10-743- 2011		US-10-743- 2011	
consensus	aggctcgcagggcagtgcatatcgctaccgcctggccgctcaggagcctgtgcttgacccc	consensus	ccaggcccatcccgtaacctggcccttcttctgcttcttctgcttctgctcactgccccggg
US-10-743- 2990	caaatccgcccccaactccctgttacccggtcactccttcacatgaggggccttccccagg	US-10-743- 3295	cccttgacactgcattccctctctctgtgagtgctcctggggcccggtaccacagtcacagt
US-10-743- 1442		US-10-743- 1442	
US-10-743- 1582		US-10-743- 1582	
US-10-743- 1577		US-10-743- 1577	
US-10-743- 1745		US-10-743- 1745	
US-10-743- 2011		US-10-743- 2011	
consensus	caaatccgcccccaactccctgttacccggtcactccttcacatgaggggccttccccagg	consensus	cccttgacactgcattccctctctctgtgagtgctcctggggcccggtaccacagtcacagt
US-10-743- 3051	gacagccgatgctctctcgtatggctcctgccttgcccttgccagtgctgcccccgctgccccacc	US-10-743- 3356	cccaggataccttttcttctctctctccagcttttataggaggtatagtgacaatt
US-10-743- 1442		US-10-743- 1442	
US-10-743- 1582		US-10-743- 1582	
US-10-743- 1577		US-10-743- 1577	
US-10-743- 1745		US-10-743- 1745	
US-10-743- 2011		US-10-743- 2011	
consensus	gacagccgatgctctctcgtatggctcctgccttgcccttgccagtgctgcccccgctgccccacc	consensus	cccaggataccttttcttctctctctccagcttttataggaggtatagtgacaatt
US-10-743- 3112	tggcctggaccctcgctcctgagccccctcaggggctctgcgccacctcaaccagcgcttgt		

US-10-743- 3417 caggacggtgtgcactcaaggatgcagcatcacacaacctgacacacgtaggcatttgtgaaa  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus caggacggtgtgcactcaaggatgcagcatcacacaacctgacacacgtaggcatttgtgaaa  
US-10-743- 3478 tgaagtccacaattgggctaattaacacaccccataccttacatggttactttcttctgtg  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus tgaagtccacaattgggctaattaacacaccccataccttacatggttactttcttctgtg  
US-10-743- 3539 gtgagaacactaaaattttaatatagaggacacacagcctgggcaacatagtggagaccctgtc  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus gtgagaacactaaaattttaatatagaggacacacagcctgggcaacatagtggagaccctgtc  
US-10-743- 3600 tctacaaatataaaaaaattatctggacgtggtggtgcacacctgtggtcccagctacttg  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus tctacaaatataaaaaaattatctggacgtggtggtgcacacctgtggtcccagctacttg  
US-10-743- 3661 ggaagctgaggctggagaaatcacttgagcctgggagcgagggttgcggtgcactccagcc  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011

consensus ggaagctgaggctggagaatcacttgagcctgggagggcgagggttgoggtgcactccagcc  
US-10-743- 3722 tgggcgacagagggagggcctatctcaaaataaataaaagggacacattttatcagct  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus tgggcgacagagggagggcctatctcaaaataaataaaagggacacattttatcagct  
US-10-743- 3783 gtagtccaccacgttcattacatcttagaacccgctaatactcataactgcacctttgttccc  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus gtagtccaccacgttcattacatcttagaacccgctaatactcataactgcacctttgttccc  
US-10-743- 3844 tgtgaccctcaactcccgtcccctccagccctgacagccactgttcaactctgtctgtg  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus tgtgaccctcaactcccgtcccctccagccctgacagccactgttcaactctgtctgtg  
US-10-743- 3905 agttccgctttttcacacgtcactcagtgaggccatgtgctgtttgtctttctgtgcctg  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus agttccgctttttcacacgtcactcagtgaggccatgtgctgtttgtctttctgtgcctg  
US-10-743- 3966 gcttatctcaacttaccacaaatgccccttcaggttcacgtgcctcacaaatggcgggctt  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745



```
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      tcggccacttacatgttttctctcgagacgcagattcaggtcccttgacgttttaaaaa
US-10-743- 4637      tttttttgtgtgtttttgtttattgagttgaattcccttctacaatttgcaaatataactcct
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      tttttttgtgtgtttttgtttattgagttgaattcccttctacaatttgcaaatataactcct
US-10-743- 4698      catcatatacatgattgcaataacccccgcctccccctgggttttgcctttttcaactgca
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      catcatatacatgattgcaataacccccgcctccccctgggttttgcctttttcaactgca
US-10-743- 4759      aatactccgcctcccccatgggggtgccttttccccctgccaataccccccaccctccccatgg
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      aatactccgcctcccccatgggggtgccttttccccctgccaataccccccaccctccccatgg
US-10-743- 4820      ggggtgccttttccctgcaataacccccaccctccccgtgggttctgccttttccctgcca
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      ggggtgccttttccctgcaataacccccaccctccccgtgggttctgccttttccctgcca
US-10-743- 4881      taccocgcctccccctgggggtgccttttcaactctgttggtttccctttgcggaagcttt
US-10-743- 1442
```

---

```
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      taccocgcctccccctgggggtgccttttcaactctgttggtttccctttgcggaagcttt
US-10-743- 4942      ctggtttgttgcactctcactgtctctatttttgccttttgcctgtgtgctgtgtggtgggcata
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      ctggtttgttgcactctcactgtctctatttttgccttttgcctgtgtgctgtgtggtgggcata
US-10-743- 5003      ttttaaaaaaatcatgtgccggaccagcctcaagaagttttccctcctacgttttcttctaa
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      ttttaaaaaaatcatgtgccggaccagcctcaagaagttttccctcctacgttttcttctaa
US-10-743- 5064      gagttttatgggtgcgggtccttaggtttgaatctttaatccgtgttgagttgatttcgta
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      gagttttatgggtgcgggtccttaggtttgaatctttaatccgtgttgagttgatttcgta
US-10-743- 5125      ggtgggtgcggatgaggccctttcatcctcctccacttttcccgaccaccactattgagga
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      ggtgggtgcggatgaggccctttcatcctcctccacttttcccgaccaccactattgagga
US-10-743- 5186      tgcccccttccccctgcgtgtgtccttggcgcttttgcctgaaggtcagttggccgtaactgt
```

```
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      tgcccccttccccgtcgctgtgtcccttggcctttgtgtgaaggtcagttggccgtaactgt
US-10-743- 5247 gcatggggacccttctctggcccccttggtgccctgtgcccccatatgtccacccccctccct
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      gcatggggacccttctctggcccccttggtgccctgtgcccccatatgtccacccccctccct
US-10-743- 5308 tactttttctccatggcatgaatcacccccagacctactatatacaaaatttatctatttatt
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      tactttttctccatggcatgaatcacccccagacctactatatacaaaatttatctatttatt
US-10-743- 5369 ttattttattttatttttttgagatggagctctcactctgtcacccaggctggagtgcagt
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      ttattttattttatttttttgagatggagctctcactctgtcacccaggctggagtgcagt
US-10-743- 5430 ggcacgatctcggtcactgcaagctccgcctcccagggttcacgccaattctcctgctcag
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      ggcacgatctcggtcactgcaagctccgcctcccagggttcacgccaattctcctgctcag
US-10-743- 5491 cctcccaagtagctgggattacggggcgccccaccatgcccggtctaaattttttgttttt
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      cctcccaagtagctgggattacggggcgccccaccatgcccggtctaaattttttgttttt
US-10-743- 5552 ttctagacacagagttccctatgttgccccccaggttggtctcgaaactcctgggtcaag
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      ttctagacacagagttccctatgttgccccccaggttggtctcgaaactcctgggtcaag
US-10-743- 5613 taatccttcacttcggcctcccaagtgtgggattacaggcatgagccattcgggccgg
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      taatccttcacttcggcctcccaagtgtgggattacaggcatgagccattcgggccgg
US-10-743- 5674 cctatttttttttttttcagacagagtttcactctgtcacccaggctgaaatgcattgcaa
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      cctatttttttttttttcagacagagtttcactctgtcacccaggctgaaatgcattgcaa
US-10-743- 5735 tgatcttggtcactgcaacttccacctcccagggttcaaaaggatttttctggtcctcagcct
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      tgatcttggtcactgcaacttccacctcccagggttcaaaaggatttttctggtcctcagcct
US-10-743- 5735 tgatcttggtcactgcaacttccacctcccagggttcaaaaggatttttctggtcctcagcct
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      tgatcttggtcactgcaacttccacctcccagggttcaaaaggatttttctggtcctcagcct
```



US-10-743- 5796 cccgaggagctgggattacagctgtgcaaccaccacacgggctaaaaatttttggaaattttt  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus cccgaggagctgggattacagctgtgcaaccaccacacgggctaaaaatttttggaaattttt  
US-10-743- 5857 ttttttactagacaggggttcaacaatgctggtcaggctggtctcgaaatttccctgacctc  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus ttttttactagacaggggttcaacaatgctggtcaggctggtctcgaaatttccctgacctc  
US-10-743- 5918 aagtgatcctcccacctcggcctcccacaaagtgtgggattacaggcgtgagccgcgatgcc  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus aagtgatcctcccacctcggcctcccacaaagtgtgggattacaggcgtgagccgcgatgcc  
US-10-743- 5979 tggccatggatatattgtaaatgttcttgtttgtgtatgttttccctcactgggctgtgcact  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus tggccatggatatattgtaaatgttcttgtttgtgtatgttttccctcactgggctgtgcact  
US-10-743- 6040 cctgaggggcggggcatctgtcccatcttccagtgctgggtccctctgtctctgggacagtgt  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011

consensus cctgaggggcggggcatctgtgccattcttcagtgctgggtcccctgtgtcttgggacagtgt  
US-10-743- 6101 atacatacagcagggtgcataaatcagttcttgactggaagggtgaggggagtcacgcacatgg  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus atacatacagcagggtgcataaatcagttcttgactggaagggtgaggggagtcacgcacatgg  
US-10-743- 6162 cagtcattggactatgtgtctgagaagcataactcacttaatcttgaagttcactttatgga  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus cagtcattggactatgtgtctgagaagcataactcacttaatcttgaagttcactttatgga  
US-10-743- 6223 ttgaagtgtgcgggttcagtgacttttaatatattaccgagttgtgtaccatcaccacca  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus ttgaagtgtgcgggttcagtgacttttaatatattaccgagttgtgtaccatcaccacca  
US-10-743- 6284 tctaatttttaaatcattttcatcatccctaaaaaagaacttcagaccactagctgtccctc  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus tctaatttttaaatcattttcatcatccctaaaaaagaacttcagaccactagctgtccctc  
US-10-743- 6345 cccctattctctccaccaccgcccctgggtcctggcgagggtgctcaacctgcatctctctg  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745

US-10-743- 2011		US-10-743- 1745	
consensus	cccctattcctcccaccaccagccctggtcctggccgagggtgtcacctgcacatctctctg	consensus	ctgggactacaggtttgccaccaccatgtcctgctaatttttttttttttttttttttgaataa
US-10-743- 6406	tggatctgccgggttgtagacatttcacacacctgcgtgcagtcctctgtgccctgcctcttt	US-10-743- 6711	gagacaggggtttctctctcatttggccagggtgtctcgaaactcctgacctcagacgatccac
US-10-743- 1442		US-10-743- 1442	
US-10-743- 1582		US-10-743- 1582	
US-10-743- 1577		US-10-743- 1577	
US-10-743- 1745		US-10-743- 1745	
US-10-743- 2011		US-10-743- 2011	
consensus	tggatctgccgggttgtagacatttcacacacctgcgtgcagtcctctgtgccctgcctcttt	consensus	gagacaggggtttctctctcatttggccagggtgtctcgaaactcctgacctcagacgatccac
US-10-743- 6467	cactcgtgtgatgtttaagttcaccccatgttgtcatctatatcggtaacttaacttctcttt	US-10-743- 6772	ctgcctcagcctcccgaagtgtttgggattacaggcacgagccactgtgcccgccatcatt
US-10-743- 1442		US-10-743- 1442	
US-10-743- 1582		US-10-743- 1582	
US-10-743- 1577		US-10-743- 1577	
US-10-743- 1745		US-10-743- 1745	
US-10-743- 2011		US-10-743- 2011	
consensus	cactcgtgtgatgtttaagttcaccccatgttgtcatctatatcggtaacttaacttctcttt	consensus	ctgcctcagcctcccgaagtgtttgggattacaggcacgagccactgtgcccgccatcatt
US-10-743- 6528	ttttttggagatgaagtccttgccttgtcacccaggctggagtgccagtggcgtgatctcg	US-10-743- 6833	cctttttactgctgactaatagtctgtgtgtaatccaccgctagaaacccactcatcag
US-10-743- 1442		US-10-743- 1442	
US-10-743- 1582		US-10-743- 1582	
US-10-743- 1577		US-10-743- 1577	
US-10-743- 1745		US-10-743- 1745	
US-10-743- 2011		US-10-743- 2011	
consensus	ttttttggagatgaagtccttgccttgtcacccaggctggagtgccagtggcgtgatctcg	consensus	cctttttactgctgactaatagtctgtgtgtaatccaccgctagaaacccactcatcag
US-10-743- 6589	gctcacagcaacttctgcctctgggttcaagtgatctcctgccttagcctcccaagtag	US-10-743- 6894	ttagtggtcatgtgggttgcttctgtctattcgctttattatgaacagtgctggataaacgt
US-10-743- 1442		US-10-743- 1442	
US-10-743- 1582		US-10-743- 1582	
US-10-743- 1577		US-10-743- 1577	
US-10-743- 1745		US-10-743- 1745	
US-10-743- 2011		US-10-743- 2011	
consensus	gctcacagcaacttctgcctctgggttcaagtgatctcctgccttagcctcccaagtag	consensus	ttagtggtcatgtgggttgcttctgtctattcgctttattatgaacagtgctggataaacgt
US-10-743- 6650	ctgggactacaggtttgaccaccacatgtcctgctaatttttttttttttttttttttgaataa	US-10-743- 6955	tcctgtgcactcttgggcatacgcctaggagtggaactgtgggtcaaatggtgactttac
US-10-743- 1442		US-10-743- 1442	
US-10-743- 1582		US-10-743- 1582	
US-10-743- 1577		US-10-743- 1582	

US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus      tcctgtgcactcttgggcatacgcctaggagtggaaactgctgggtcaaatggtagctttac  
US-10-743- 7016    gtttaacgttctgaggagccgcaggcggttttaacacagtgactgcaccatttcacattcc  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus      gtttaacgttctgaggagccgcaggcggttttaacacagtgactgcaccatttcacattcc  
US-10-743- 7077    tgccaacaatgtgtgagaattccaatttctctacatccccaacattttctcttaaaaaaa  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus      tgccaacaatgtgtgagaattccaatttctctacatccccaacattttctcttaaaaaaa  
US-10-743- 7138    gaaaaaagaacatagccatctaagtggatgtggagcagactgtccctctgggtttgggttt  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus      gaaaaaagaacatagccatctaagtggatgtggagcagactgtccctctgggtttgggttt  
US-10-743- 7199    gcgttgcttttatggctcatgatgtctgagtctctctccatgctcgtcatggggattcgat  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus      gcgttgcttttatggctcatgatgtctgagtctctctccatgctcgtcatggggattcgat  
US-10-743- 7260    atctactttgggaaatgcttattcaagtccctttgtccacatttgactgggttgcttgcctt  
US-10-743- 1442

US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus      atctactttgggaaatgcttattcaagtcctttgtccacatttgactgggttgcttgcctt  
US-10-743- 7321    tttatttcatttactacgatgacagccctacatggaaggattttgttttttgtaatcccat  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus      tttatttcatttactacgatgacagccctacatggaaggattttgttttttgtaatcccat  
US-10-743- 7382    taacctgagtgagaatgaattgccagttgctcaaggcccttcagctctttagggaggagcct  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus      taacctgagtgagaatgaattgccagttgctcaaggcccttcagctctttagggaggagcct  
US-10-743- 7443    ggaacctggagtgctccgggctctctggcaaaagctccaatcccggcctcagtccttgaggcct  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus      ggaacctggagtgctccgggctctctggcaaaagctccaatcccggcctcagtccttgaggcct  
US-10-743- 7504    ggtcctcaaccagctttctctctccaccgtgccatggaggaagcccagacctctctgcacgg  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus      ggtcctcaaccagctttctctctccaccgtgccatggaggaagcccagacctctctgcacgg  
US-10-743- 7565    ctggcctggggttggttcacgactgagtcagggtgtcccccagaaaggatgtcaactggtcaca

```
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      ctggcctgggtgtgttcacgactgagtcacaggtgtccccagaacggatgtcaactggtcaca
US-10-743- 7626 gtgttcctcgtgaataggtgacccccaggcacagggtgttctcctgatcataggtaacccaggca
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      gtgttcctcgtgaataggtgacccccaggcacagggtgttctcctgatcataggtaacccaggca
US-10-743- 7687 caggtgtccccagtcacaggtgtctccaggcacaggtgtccccagtcacaggtgtccccaggt
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      caggtgtccccagtcacaggtgtctccaggcacaggtgtccccagtcacaggtgtccccaggt
US-10-743- 7748 cacaggcgtccccaggcacaggtgtccctggtcacagatgtccccaggcacaggtgtccca
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      cacaggcgtccccaggcacaggtgtccctggtcacagatgtccccaggcacaggtgtccca
US-10-743- 7809 ggacacaggtgtctccaggcacaggcgtcccaggtcacaggtgtccccggtcacaggtgtcc
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      ggacacaggtgtctccaggcacaggcgtcccaggtcacaggtgtccccggtcacaggtgtcc
US-10-743- 7870 ctgggtcacaggtgtctccaggcacaggtgtccctggtcacaggtgtccccggtcacaggtgt
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      ctgggtcacaggtgtctccaggcacaggtgtccctggtcacaggtgtccccggtcacaggtgt
US-10-743- 7931 tcccaggtcacaggtgtccccaggcacaggtgtccccggtcacaggtgtctccgggtcacag
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      tcccaggtcacaggtgtccccaggcacaggtgtccccggtcacaggtgtctccgggtcacag
US-10-743- 7992 gtgtccccaggcataggtgtccctggtcacaggcacccatggtcacaggtgtccccaggca
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      gtgtccccaggcataggtgtccctggtcacaggcacccatggtcacaggtgtccccaggca
US-10-743- 8053 caggtgtcctggtcacaggtgtcccagtcacagctgtccccggtcacaggtgtctccagggc
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      caggtgtcctggtcacaggtgtcccagtcacagctgtccccggtcacaggtgtctccagggc
US-10-743- 8114 acaggtgttcccggtcacaggtgtccccaggcacaggtgtccccggtcacaggtgtccccag
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      acaggtgttcccggtcacaggtgtccccaggcacaggtgtccccggtcacaggtgtccccag
```

```
consensus      acagtggtcccggtcacaggtgtccccaggcacacaggtgtccccgtcacaggtgtccccag
US-10-743- 8175 gcacaggaggttcctgggtcacaggtgtccccaggcacacaggtgtccccaggcacacaggtgtccccag
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      gcacaggaggttcctgggtcacaggtgtccccaggcacacaggtgtccccaggcacacaggtgtccccag
US-10-743- 8236 ggaacagagagaaacagagacacacaaagaaagagagtgagagacagagaagaatgggaaca
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      ggaacagagagaaacagagacacacaaagaaagagagtgagagacagagaagaatgggaaca
US-10-743- 8297 gaaatggttgagaaaaagcatccagtagacatgaatagagaggaaggagggggagc
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      gaaatggttgagaaaaagcatccagtagacatgaatagagaggaaggagggggagc
US-10-743- 8358 ggcagcagagagaccagggaggctgcagtgctggaccctcaccacacatttccattctgcc
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      ggcagcagagagaccagggaggctgcagtgctggaccctcaccacacatttccattctgcc
US-10-743- 8419 cttcctggggaagacttccagaaaagtgggccaggctgaggggacgatgaggacacagag
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
```

```
US-10-743- 2011
consensus      cttcctggggaagacttccagaaaaagtgggccagggtgaggggacgatgaggacacacagagg
US-10-743- 8480 cccagggggaggaggagggccaccggaggggctgtggtcagctcaagcctct
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      cccagggggaggaggagggccaccggaggggctgtggtcagctcaagcctct
US-10-743- 8541 ggagtcaggataaaatcctctgacctttgacctccgacctcctctccttgggtccaggct
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      ggagtcaggataaaatcctctgacctttgacctccgacctcctctccttgggtccaggct
US-10-743- 8602 cccacacagcttccatgaccaaatcttacaggaagctgaaggagcagtcgggtgaggggtc
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      cccacacagcttccatgaccaaatcttacaggaagctgaaggagcagtcgggtgaggggtc
US-10-743- 8663 tgtaagtcaccgccaggggcacagaacggaggttggcaggggagagagaccctgggctgc
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      tgtaagtcaccgccaggggcacagaacggaggttggcaggggagagagaccctgggctgc
US-10-743- 8724 cgtctgccttcaacctgcacatcaggcctgtgtggggggtgtcaccatccttcaatccctgg
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
```

US-10-743- 1745	US-10-743- 1577
US-10-743- 2011	US-10-743- 1745
consensus	ctggcctccctgcaaggcagctccgcgccccggggccctgcctctgagagcagggtgtgca
US-10-743- 8785	US-10-743- 9090
US-10-743- 1442	US-10-743- 1442
US-10-743- 1582	US-10-743- 1582
US-10-743- 1577	US-10-743- 1577
US-10-743- 1745	US-10-743- 1745
US-10-743- 2011	US-10-743- 2011
consensus	ggctcttctatgggtacctggcccatccccagaacgacctgactgtccctccccgacc
US-10-743- 8846	US-10-743- 9151
US-10-743- 1442	US-10-743- 1442
US-10-743- 1582	US-10-743- 1582
US-10-743- 1577	US-10-743- 1577
US-10-743- 1745	US-10-743- 1745
US-10-743- 2011	US-10-743- 2011
consensus	tgcacccagacatggacactcacctccccaaacctgagacattcaggtccacactgggg
US-10-743- 8907	US-10-743- 9212
US-10-743- 1442	US-10-743- 1442
US-10-743- 1582	US-10-743- 1582
US-10-743- 1577	US-10-743- 1577
US-10-743- 1745	US-10-743- 1745
US-10-743- 2011	US-10-743- 2011
consensus	tgcacccagacatggacactcacctccccaaacctgagacattcaggtccacactgggg
US-10-743- 8968	US-10-743- 9273
US-10-743- 1442	US-10-743- 1442
US-10-743- 1582	US-10-743- 1582
US-10-743- 1577	US-10-743- 1577
US-10-743- 1745	US-10-743- 1745
US-10-743- 2011	US-10-743- 2011
consensus	cctgggccccctcaagtgcattgggactggggtgccttggcgccctctctgtgagtattc
US-10-743- 8929	US-10-743- 9334
US-10-743- 1442	US-10-743- 1442
US-10-743- 1582	US-10-743- 1582

US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus acccccgagactttcaggtccacactggggcctgggccccctcaagttgcacatggggactgg  
US-10-743- 9395 gctgctcgggcctcttctgtgagtgcttacacacagagcctgcctcctgtccgggtg  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus gctgctcgggcctcttctgtgagtgcttacacacagagcctgcctcctgtccgggtg  
US-10-743- 9456 atgttgggtcgtccctcctctgggagacactgcaggggctgttgcctctgggtccctcctgg  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus atgttgggtcgtccctcctctgggagacactgcaggggctgttgcctctgggtccctcctgg  
US-10-743- 9517 agatgcaagccccgggcctgcctgttctgtatgtgtgtattcattaaagccccatgccagcg  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus agatgcaagccccgggcctgcctgttctgtatgtgtgtattcattaaagccccatgccagcg  
US-10-743- 9578 ggggtctccgcaagaacagcacagtcagtcgtgagggggctaatgaggccctgatttctcca  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus ggggtctccgcaagaacagcacagtcagtcgtgagggggctaatgaggccctgatttctcca  
US-10-743- 9639 ggggcaggcaggagggagccccatagggttgctgaggacccagggtgtgcaactgtgcaactgtggga

US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus ggggcaggcaggacgggagccccatgagggttgctgaggacccagggaatgtgcaactgtggga  
US-10-743- 9700 agccaccaccaccagaaagcggcaagggaaggaagttagtggtgccagaacatgggc  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus agccaccaccaccagaaagcggcaagggaaggaagttagtggtgccagaacatgggc  
US-10-743- 9761 taaacgaggcagccatggaaagggatgcagacaggaagtggagaggaaggcggttctcca  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus taaacgaggcagccatggaaagggatgcagacaggaagtggagaggaaggcggttctcca  
US-10-743- 9822 ggagccctaggacctgctctggggctgctgctgctgagcccaactgggaaccagagcacag  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus ggagccctaggacctgctctggggctgctgctgctgagcccaactgggaaccagagcacag  
US-10-743- 9883 gataatgggtgacacctggtgatgatggcgatggagatgattatgatggtgatgatggtggtg  
US-10-743- 1442  
US-10-743- 1582  
US-10-743- 1577  
US-10-743- 1745  
US-10-743- 2011  
consensus gataatgggtgacacctggtgatgatggcgatggagatgattatgatggtgatgatggtggtg

```
US-10-743- 9944 atggtggtgatgatggtgatgatggtgacggtggtgatggtgatggtgatggtgatggtga
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      atggtggtgatgatggtgatgatggtgacggtggtgatggtgatggtgatggtgatggtga

US-10-743- 10005 tgatggtgacggtggtgatggtgctgtgatgatggtgatggtgatggtgatggtgacggt
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      tgatggtgacggtggtgatggtgctgtgatgatggtgatggtgatggtgatggtgacggt

US-10-743- 10066 gatgatgatggtgacggtgatgatggtgatgatggtgatggtgatggtgatggtgatggtg
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      gatgatgatggtgacggtgatgatggtgatgatggtgatggtgatggtgatggtgatggtg

US-10-743- 10127 gtgatgatggtggtgatgatgatgatggtgatgatggtgatggtgatggtgatggtgatga
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      gtgatgatggtggtgatgatgatgatggtgatgatggtgatggtgatggtgatggtgatga

US-10-743- 10188 tggatggtgatcatggtgatgatggtgatggtgatggtgatggtgatggtgatggtggt
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      tggatggtgatcatggtgatgatggtgatggtgatggtgatggtgatggtgatggtggt

US-10-743- 10127 tggatggtgatcatggtgatgatggtgatggtgatggtgatggtgatggtgatggtggt
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
consensus      tggatggtgatcatggtgatgatggtgatggtgatggtgatggtgatggtgatggtggt
```

```
US-10-743- 10249 gatgatggtgatggtgatgatgatggtgatggtgatggtgatggtgatggttccaccacggggcg
US-10-743- 1442
US-10-743- 1582
US-10-743- 1577
US-10-743- 1745
US-10-743- 2011
```

consensus gatgatggtgatggtgatgatgatggtgatggtgatggtgatggtgatggttccaccacggggcg

Alignment score = -209195.00

Scoring matrix:

	1	2	3	4	5	6
1	-7900	-7200	-7875	-10045	-8715	
2		730	1287	-638	680	
3			676	-1414	-123	
4				-594	736	
5					403	
6						

-----